__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	QOL scores were not significantly different among the regimens.
__label__noRel	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	QOL scores were not significantly different among the regimens.
__label__Support	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	QOL scores were not significantly different among the regimens.
__label__noRel	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	QOL scores were not significantly different among the regimens.
__label__Support	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	QOL scores were not significantly different among the regimens.
__label__Support	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	QOL scores were not significantly different among the regimens.
__label__Support	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	QOL scores were not significantly different among the regimens.
__label__noRel	Quality of life (QOL) declined significantly over the 6 months.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	QOL scores were not significantly different among the regimens.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	QOL scores were not significantly different among the regimens.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	QOL scores were not significantly different among the regimens.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	QOL scores were not significantly different among the regimens.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	QOL scores were not significantly different among the regimens.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	QOL scores were not significantly different among the regimens.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	QOL scores were not significantly different among the regimens.	Quality of life (QOL) declined significantly over the 6 months.
__label__Support	QOL scores were not significantly different among the regimens.	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non-small-cell lung cancer (NSCLC).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P =. 048).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Comparing survival for the two dose levels of paclitaxel revealed no significant difference.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P =.152).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P =.246).
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	Quality of life (QOL) declined significantly over the 6 months.
__label__noRel	paclitaxel (135 mg/m(2)) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.	QOL scores were not significantly different among the regimens.
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__Support	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__Support	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__noRel	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.	Measurable improvement in a general QOL measure was not demonstrated.
__label__noRel	Measurable improvement in a general QOL measure was not demonstrated.	Menopausal symptoms (e.g., hot flashes, vaginal dryness, and stress urinary incontinence) are very common in breast cancer survivors and cannot be managed with standard estrogen replacement therapy (ERT) in these patients.
__label__noRel	Measurable improvement in a general QOL measure was not demonstrated.	Patients receiving the intervention demonstrated statistically significant improvement (P =.0004) in menopausal symptoms but no significant change in vitality (P =.77).
__label__noRel	Measurable improvement in a general QOL measure was not demonstrated.	Sexual functioning was statistically significantly improved (P =.04) in the treatment group compared with the usual-care group.
__label__Attack	Measurable improvement in a general QOL measure was not demonstrated.	A clinical assessment and intervention program for menopausal symptom management in breast cancer survivors is feasible and acceptable to patients, leading to reduction in symptoms and improvement in sexual functioning.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Lower scores were associated with the combination therapy.
__label__Support	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Lower scores were associated with the combination therapy.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__Support	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Lower scores were associated with the combination therapy.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Lower scores were associated with the combination therapy.
__label__Support	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Lower scores were associated with the combination therapy.
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__Support	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Lower scores were associated with the combination therapy.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Lower scores were associated with the combination therapy.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Lower scores were associated with the combination therapy.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Lower scores were associated with the combination therapy.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Lower scores were associated with the combination therapy.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Lower scores were associated with the combination therapy.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Lower scores were associated with the combination therapy.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Lower scores were associated with the combination therapy.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Lower scores were associated with the combination therapy.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Lower scores were associated with the combination therapy.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.	Treatment, particularly the combination therapy, was associated with a decrease in QOL.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Complete or partial responses were achieved by 12% of patients treated with IFNalpha2a plus 13-CRA and 6% of patients treated with IFNalpha2a (P =.14).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Median duration of response (complete and partial combined) in the group treated with the combination was 33 months (range, 9 to 50 months), versus 22 months (range, 5 to 38 months) for the second group (P =.03).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Nineteen percent of patients treated with IFNalpha2a plus 13-CRA were progression-free at 24 months, compared with 10% of patients treated with IFNalpha2a alone (P =.05).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Median survival time for all patients was 15 months, with no difference in survival between the two treatment arms (P =.26).
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	QOL decreased during the first 8 weeks of treatment, and a partial recovery followed.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Lower scores were associated with the combination therapy.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	Response proportion and survival did not improve significantly with the addition of 13-CRA to IFNalpha2a therapy in patients with advanced RCC.
__label__noRel	Treatment, particularly the combination therapy, was associated with a decrease in QOL.	13-CRA may lengthen response to IFNalpha2a therapy in patients with IFNalpha2a-sensitive tumors.
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	A steady improvement in quality of life was also observed in both groups.
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	There were no clinically significant differences between the groups.
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	A steady improvement in quality of life was also observed in both groups.
__label__noRel	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	There were no clinically significant differences between the groups.
__label__noRel	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__Support	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	A steady improvement in quality of life was also observed in both groups.
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	There were no clinically significant differences between the groups.
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	A steady improvement in quality of life was also observed in both groups.	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	A steady improvement in quality of life was also observed in both groups.	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	A steady improvement in quality of life was also observed in both groups.	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	A steady improvement in quality of life was also observed in both groups.	There were no clinically significant differences between the groups.
__label__noRel	A steady improvement in quality of life was also observed in both groups.	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	A steady improvement in quality of life was also observed in both groups.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__Support	A steady improvement in quality of life was also observed in both groups.	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	A steady improvement in quality of life was also observed in both groups.	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	There were no clinically significant differences between the groups.	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	There were no clinically significant differences between the groups.	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	There were no clinically significant differences between the groups.	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	There were no clinically significant differences between the groups.	A steady improvement in quality of life was also observed in both groups.
__label__noRel	There were no clinically significant differences between the groups.	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	There were no clinically significant differences between the groups.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__Support	There were no clinically significant differences between the groups.	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	There were no clinically significant differences between the groups.	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	A steady improvement in quality of life was also observed in both groups.
__label__noRel	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	There were no clinically significant differences between the groups.
__label__noRel	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__Support	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	A steady improvement in quality of life was also observed in both groups.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	There were no clinically significant differences between the groups.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	A steady improvement in quality of life was also observed in both groups.
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	There were no clinically significant differences between the groups.
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__noRel	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.	Prompt diagnosis and effective treatment is, therefore, essential.
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	In the context of chronic physical illness, such as breast cancer, depression is associated with increased morbidity, longer periods of hospitalization, and greater overall disability.
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	After 8-weeks treatment, depressive symptomatology had improved markedly and to a similar extent in both groups on the Montgomery Asberg Depression Rating Scale.
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	Clinical global impression (CGI) Global improvement and Patient global evaluation scales indicated that patients were minimally to much improved at study endpoint: a change from moderately/mildly ill to borderline ill on the CGI severity of Illness scale.
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	A steady improvement in quality of life was also observed in both groups.
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	There were no clinically significant differences between the groups.
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	In total, 47 (53.4%) patients in the paroxetine group and 53 (59.6%) patients in the amitriptyline group had adverse experiences, the most common of which were the well-recognized side-effects of the antidepressant medications or chemotherapy.
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	Anticholinergic effects were almost twice as frequent in the amitriptyline group (19.1%) compared with paroxetine (11.4%).
__label__noRel	Prompt diagnosis and effective treatment is, therefore, essential.	paroxetine is a suitable alternative to amitriptyline for the treatment of depression in patients with breast cancer.
__label__noRel	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).
__label__noRel	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.
__label__noRel	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
__label__Support	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
__label__noRel	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.	this regimen could not be recommended for a phase III randomized study.
__label__noRel	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.
__label__noRel	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.
__label__noRel	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
__label__Support	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
__label__noRel	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).	this regimen could not be recommended for a phase III randomized study.
__label__noRel	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.
__label__noRel	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).
__label__noRel	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
__label__Support	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
__label__noRel	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.	this regimen could not be recommended for a phase III randomized study.
__label__noRel	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.
__label__noRel	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).
__label__noRel	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.
__label__noRel	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
__label__noRel	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.	this regimen could not be recommended for a phase III randomized study.
__label__noRel	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.
__label__noRel	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).
__label__noRel	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.
__label__noRel	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
__label__Support	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;	this regimen could not be recommended for a phase III randomized study.
__label__noRel	this regimen could not be recommended for a phase III randomized study.	At a median follow-up time of 13.5 months (range 1-28+) at June 2001, among 26 patients enrolled 12 (46.1%) were still alive and 9 (75%) of them were progression-free.
__label__noRel	this regimen could not be recommended for a phase III randomized study.	The median duration of response was 9 months (range 0-25+), the median progression-free survival was 10.5 months (range 0-28+), the median overall survival time was 9 months (range 1-22).
__label__noRel	this regimen could not be recommended for a phase III randomized study.	The toxicity was significant and consisted mainly of mucositis and, to a lesser extent, neutropenia/thrombocytopenia.
__label__noRel	this regimen could not be recommended for a phase III randomized study.	the low serum levels of leptin and the high serum levels of proinflammatory cytokines in advanced stage cancer patients were confirmed.
__label__noRel	this regimen could not be recommended for a phase III randomized study.	this sequential induction chemotherapy and chemoradiotherapy program has been found moderately active and significantly toxic;
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__Support	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.	but the differences were not statistically significant.
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__Support	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.	but the differences were not statistically significant.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,	but the differences were not statistically significant.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	There were no differences in the proportions of patients in the two groups that reported worsening.	but the differences were not statistically significant.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__noRel	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.	but the differences were not statistically significant.
__label__noRel	but the differences were not statistically significant.	After completion of chemotherapy, patients treated with trastuzumab and chemotherapy reported significant improvement in fatigue (P <.05) as compared with their baseline scores.
__label__noRel	but the differences were not statistically significant.	Higher proportions of patients receiving the combined therapy achieved improvement in global QOL (P <.05) than did patients treated with chemotherapy alone.
__label__Attack	but the differences were not statistically significant.	Higher proportions of the combined therapy group also achieved improvement in physical and role functioning and in fatigue as compared with the chemotherapy group,
__label__noRel	but the differences were not statistically significant.	There were no differences in the proportions of patients in the two groups that reported worsening.
__label__noRel	but the differences were not statistically significant.	Statistically significantly higher proportions of patients treated with a combination of trastuzumab and chemotherapy reported improved global QOL than did patients treated by chemotherapy alone.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	CP resulted in more anastomotic leaks.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	CP resulted in more anastomotic leaks.
__label__Support	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	CP resulted in more anastomotic leaks.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	CP resulted in more anastomotic leaks.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	CP resulted in more anastomotic leaks.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	CP resulted in more anastomotic leaks.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	CP resulted in more anastomotic leaks.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	CP resulted in more anastomotic leaks.
__label__noRel	CP resulted in more anastomotic leaks.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	CP resulted in more anastomotic leaks.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	CP resulted in more anastomotic leaks.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	CP resulted in more anastomotic leaks.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	CP resulted in more anastomotic leaks.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	CP resulted in more anastomotic leaks.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	CP resulted in more anastomotic leaks.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	CP resulted in more anastomotic leaks.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	the 8-mg dose was associated with renal function deterioration.
__label__Support	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	the 8-mg dose was associated with renal function deterioration.
__label__Support	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	the 8-mg dose was associated with renal function deterioration.
__label__noRel	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	the 8-mg dose was associated with renal function deterioration.
__label__noRel	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	the 8-mg dose was associated with renal function deterioration.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	the 8-mg dose was associated with renal function deterioration.	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	the 8-mg dose was associated with renal function deterioration.	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Bone metastases are a common cause of morbidity in patients with prostate carcinoma.
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	A greater proportion of patients who received placebo had skeletal-related events than those who received zoledronic acid at 4 mg (44.2% versus 33.2%; difference = -11.0%, 95% confidence interval [CI] = -20.3% to -1.8%; P =.021) or those who received zoledronic acid at 8/4 mg (38.5%; difference versus placebo = -5.8%, 95% CI = -15.1% to 3.6%; P =.222).
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Median time to first skeletal-related event was 321 days for patients who received placebo, was not reached for patients who received zoledronic acid at 4 mg (P =.011 versus placebo), and was 363 days for those who received zoledronic acid at 8/4 mg (P =.491 versus placebo).
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Compared with urinary markers in patients who received placebo, urinary markers of bone resorption were statistically significantly decreased in patients who received zoledronic acid at either dose (P =.001).
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Pain and analgesic scores increased more in patients who received placebo than in patients who received zoledronic acid,
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	there were no differences in disease progression, performance status, or quality-of-life scores among the groups.
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	Zoledronic acid at 4 mg given as a 15-minute infusion was well tolerated,
__label__noRel	Zoledronic acid at 4 mg reduced skeletal-related events in prostate cancer patients with bone metastases.	the 8-mg dose was associated with renal function deterioration.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	no other differences in QoL were detected.
__label__noRel	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	no other differences in QoL were detected.
__label__Support	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	no other differences in QoL were detected.
__label__Support	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	no other differences in QoL were detected.
__label__Support	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	no other differences in QoL were detected.
__label__noRel	Peripheral neuropathy and alopecia were more common with CVP.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	Patients receiving fludarabine had higher scores for social function (P =.008);	no other differences in QoL were detected.
__label__Support	Patients receiving fludarabine had higher scores for social function (P =.008);	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	no other differences in QoL were detected.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	no other differences in QoL were detected.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	no other differences in QoL were detected.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	no other differences in QoL were detected.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	no other differences in QoL were detected.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	no other differences in QoL were detected.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	no other differences in QoL were detected.	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	There was no difference in response rates, with 64% (complete response [CR], 9%) for fludarabine versus 52% (CR, 7%) for CVP (P =.72).
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	With a median follow-up of 42 months, median PFS (11 months v 9.1 months; P =.03) and TFS (15 months v 11 months; P =.02) were superior in patients receiving fludarabine.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	No difference in median overall survival was detected (57 months for fludarabine v 44 months for CVP; P =.95).
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Three patients receiving fludarabine died of treatment-related toxicity compared with none of the patients receiving CVP.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Peripheral neuropathy and alopecia were more common with CVP.
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	Patients receiving fludarabine had higher scores for social function (P =.008);
__label__noRel	In recurrent low-grade lymphoma, fludarabine improves PFS, TFS, and social function scores in comparison with CVP but does not improve OS.	no other differences in QoL were detected.
__label__noRel	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).
__label__noRel	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.
__label__noRel	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.
__label__Support	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.
__label__noRel	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.	Anemia, highly common among cancer patients, is often an underlying cause of cancer-related fatigue and other quality-of-life (QOL) deficits.
__label__noRel	In the clinical trial, treatment with epoetin alfa overcame much of the QOL deficit seen in anemic cancer patients compared with the norm population sample.	Comparison of the population norm and clinical trial data showed that treatment with epoetin alfa resulted in clinically meaningful as well as statistically significant improvements in QOL (P <.01).
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	At radical prostatectomy, pathological variables were not significantly different in the two groups.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__Support	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__Support	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__Support	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__noRel	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	At radical prostatectomy, pathological variables were not significantly different in the two groups.
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	Serum testosterone level was significantly higher (mean 359.2 compared to 10.5, P < 0.001),
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	complete response rate of PSA (13% compared to 57%, P = 0.028) and rate of downsizing of prostate volume (mean, -17.7% compared to -35.4%, P = 0.038) were significantly lower in the flutamide group than in the LHRH group.
__label__noRel	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	After neoadjuvant hormone therapy, the scores on the sexual problem domain of EORTC-P (P = 0.033) and sexual desire score of SMUF (P = 0.021) were significantly higher in the flutamide group than in the LHRH group.
__label__Support	At a median follow-up of 34 months after prostatectomy, biochemical failure-free survival rate in the flutamide group did not differ from that in the LHRH group.	This study suggests that flutamide monotherapy can be an acceptable modality as an option for neoadjuvant hormone therapy.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Efficacy was similar for the 250- and 500-mg/d groups.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__Support	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__Support	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	Drug-related toxicities were more frequent in the higher-dose group.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Drug-related toxicities were more frequent in the higher-dose group.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__Support	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	At 250 mg/d, gefitinib had a favorable AE profile.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__Support	At 250 mg/d, gefitinib had a favorable AE profile.	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Efficacy was similar for the 250- and 500-mg/d groups.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Objective tumor response rates were 18.4% (95% confidence interval [CI], 11.5 to 27.3) and 19.0% (95% CI, 12.1 to 27.9); among evaluable patients, symptom improvement rates were 40.3% (95% CI, 28.5 to 53.0) and 37.0% (95% CI, 26.0 to 49.1); median progression-free survival times were 2.7 and 2.8 months; and median overall survival times were 7.6 and 8.0 months, respectively.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Adverse events (AEs) at both dose levels were generally mild (grade 1 or 2) and consisted mainly of skin reactions and diarrhea.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Symptom improvements were recorded for 69.2% (250 mg/d) and 85.7% (500 mg/d) of patients with a tumor response.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Drug-related toxicities were more frequent in the higher-dose group.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Withdrawal due to drug-related AEs was 1.9% and 9.4% for patients receiving gefitinib 250 and 500 mg/d, respectively.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in these patients.
__label__noRel	Gefitinib 250 mg/d is an important, novel treatment option for patients with pretreated advanced NSCLC.	At 250 mg/d, gefitinib had a favorable AE profile.
__label__noRel	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity
__label__noRel	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.
__label__noRel	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.
__label__noRel	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.
__label__noRel	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).	The patient accrual to the trial is satisfactory
__label__noRel	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
__label__noRel	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.
__label__noRel	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.
__label__noRel	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.
__label__noRel	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity	The patient accrual to the trial is satisfactory
__label__Support	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.
__label__noRel	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.	The patient accrual to the trial is satisfactory
__label__Support	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.
__label__noRel	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.	The patient accrual to the trial is satisfactory
__label__Support	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.
__label__noRel	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.	The patient accrual to the trial is satisfactory
__label__Support	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	The patient accrual to the trial is satisfactory	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
__label__noRel	The patient accrual to the trial is satisfactory	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity
__label__noRel	The patient accrual to the trial is satisfactory	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.
__label__noRel	The patient accrual to the trial is satisfactory	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.
__label__noRel	The patient accrual to the trial is satisfactory	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.
__label__noRel	The patient accrual to the trial is satisfactory	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
__label__noRel	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
__label__noRel	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity
__label__noRel	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.
__label__noRel	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.
__label__noRel	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.
__label__noRel	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.	The patient accrual to the trial is satisfactory
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__noRel	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	The TC regimen was associated with a higher frequency of hematologic toxicity,	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__Support	The TC regimen was associated with a higher frequency of hematologic toxicity,	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__Attack	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__noRel	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__Support	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue.
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	The proportion of patients without progression at 2 years was not statistically significantly different between the two treatment arms (40.0% for PT versus 37.5% for TC, difference = 2.5%, one-sided 95% confidence interval [CI] = - infinity to 8.2%).
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	Median progression-free survival time in the TC arm (17.2 months, 95% CI = 15.2 to 19.3 months) and the PT arm (19.1 months, 95% CI = 16.7 to 21.5 months) were also not statistically significantly different;
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	the same was true of median overall survival time (43.3 months, 95% CI = 37.2 to 47.8 months versus 44.1 months, 95% CI = 40.2 to 49.4 months, for the TC and PT arms, respectively).
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	The TC regimen was associated with a higher frequency of hematologic toxicity,
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	but a lower frequency of gastrointestinal and neurologic toxicity, than the PT regimen.
__label__noRel	The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should, therefore, be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.	Mean global quality-of-life scores at the end of treatment were statistically significantly better in the TC arm than in the PT arm (65.25 versus 51.97, respectively; difference = -13.28, 95% CI = -18.88 to -7.68).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__Support	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__noRel	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__Support	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Three years after radiotherapy, urinary incontinence was reported by 35% of patients, but only 6% required the use of a pad or other protective device.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Patients reported increased leakage with a full bladder (urge incontinence) between the 2 and 3-year questionnaires (42% versus 50%; P = 0.03).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	At 3 years, 33% of patients reported rectal bleeding compared with 47% at 2 years (P = 0.006).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Patients in the 78-Gy arm reported more frequent bowel movements at 3 years and less change in bowel function at 2 years than patients in the 70-Gy arm.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	Before radiotherapy, 84% of patients reported erections adequate for intercourse at least a few times during the previous year.
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	After 2 and 3 years, this had decreased to 49% and 41%, respectively (P <0.02).
__label__noRel	Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased.	By patient-reported questionnaire, 78 Gy produced an increase in bowel movement frequency and no increase in bladder or sexual side effects at 3 years compared with 70 Gy.
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	No consistent influence on QOL was detected.
__label__Support	There was no significant difference in RR, RD, or PFS between arms.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	There was no significant difference in RR, RD, or PFS between arms.	Additional studies of DPPE are warranted.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	No consistent influence on QOL was detected.
__label__Support	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).	Additional studies of DPPE are warranted.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	No consistent influence on QOL was detected.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.	Additional studies of DPPE are warranted.
__label__noRel	No consistent influence on QOL was detected.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	No consistent influence on QOL was detected.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	No consistent influence on QOL was detected.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	No consistent influence on QOL was detected.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__Support	No consistent influence on QOL was detected.	Additional studies of DPPE are warranted.
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	No consistent influence on QOL was detected.
__label__Support	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.	Additional studies of DPPE are warranted.
__label__noRel	Additional studies of DPPE are warranted.	There was no significant difference in RR, RD, or PFS between arms.
__label__noRel	Additional studies of DPPE are warranted.	DPPE plus DOX was statistically superior to DOX in OS (hazard ratio, 0.66; 95% CI, 0.48 to 0.91; P =.021).
__label__noRel	Additional studies of DPPE are warranted.	DPPE plus DOX was associated with more gastrointestinal and CNS toxicity.
__label__noRel	Additional studies of DPPE are warranted.	No consistent influence on QOL was detected.
__label__noRel	Additional studies of DPPE are warranted.	This study demonstrated no advantage in RR, RD, or PFS but significantly superior OS for DPPE plus DOX.
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__Support	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__noRel	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__Support	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__Attack	however, there was no significant difference between changes in the scores of both groups (p=0.67).	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	however, there was no significant difference between changes in the scores of both groups (p=0.67).	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__noRel	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	Aerobic exercise and psychosocial interventions have been shown to reduce the severity of this symptom in cancer patients.
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	Physical performance of the training group improved significantly during the programme (9.4+/-20 watts, p=0.01) but remained unchanged in the relaxation group (1.5+/-14.8 watts, p=0.37).
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	Fatigue and global health scores improved in both groups during the intervention (fatigue: training group 21%, relaxation group 19%; global health of both groups 19%, p for all < or =0.01);
__label__noRel	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	however, there was no significant difference between changes in the scores of both groups (p=0.67).
__label__Attack	However, exercise is not better than progressive relaxation training for the treatment of fatigue in this setting.	We conclude that a structured aerobic training programme improves the physical performance of patients recovering from surgery for solid tumours.
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	The incidence of toxicity in the groups was similar.
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	The incidence of toxicity in the groups was similar.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	The incidence of toxicity in the groups was similar.
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	The incidence of toxicity in the groups was similar.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	The incidence of toxicity in the groups was similar.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	The incidence of toxicity in the groups was similar.	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	The incidence of toxicity in the groups was similar.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	The incidence of toxicity in the groups was similar.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__noRel	The incidence of toxicity in the groups was similar.	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__Support	The incidence of toxicity in the groups was similar.	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	The incidence of toxicity in the groups was similar.
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__noRel	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__Support	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	The incidence of toxicity in the groups was similar.
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__Support	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	The incidence of toxicity in the groups was similar.
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__Support	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, -3.8 to +5.3) compared with 2.8 g/dL (range, -2.2 to +7.5) for epoetin-treated patients (P < .0001).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	During the study, 31.7% of placebo-treated patients achieved a > or = 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively.
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	The incidence of toxicity in the groups was similar.
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with -2.1 for the nonresponders (P = .006).
__label__noRel	These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.	Epoetin alfa significantly improved HgB and reduced transfusions in this patient population.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	There were no group differences with respect to survival.
__label__Support	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	There were no group differences with respect to survival.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__Support	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	There were no group differences with respect to survival.
__label__Support	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	There were no group differences with respect to survival.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	There were no group differences with respect to survival.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	There were no group differences with respect to survival.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	There were no group differences with respect to survival.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	There were no group differences with respect to survival.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	There were no group differences with respect to survival.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	There were no group differences with respect to survival.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	There were no group differences with respect to survival.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__Support	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	There were no group differences with respect to survival.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__Support	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	There were no group differences with respect to survival.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	The group treated with oral Etoposide had a significantly better QOL than the radiotherapy group for the total FLI-C score (adjusted mean plus standard error at 3-months 89 +/- 3 vs. 76 +/- 3; p = 0.004) and for the hardship (11 +/- 0.4 vs. 9 +/- 0.4; p = 0.001); social (10 +/- 0.4 vs. 8 +/- 0.4; p = 0.001) and nausea (9 +/- 0.4 vs. 8 +/- 0.4; p = 0.002) subscales.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	In addition, on the physical and psychological subscales, the Etoposide group had a significantly better QOL than the other 3 treatment groups (p < 0.04).
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	The 3-drug combination, supportive care and radiotherapy groups did not differ significantly from each other with respect to the total FLI-C score or its subscales.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	There were no group differences with respect to survival.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	Oral Etoposide therapy resulted in better total FLI-C QOL score than radiotherapy.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	Etoposide resulted in better physical and psychological subscale scores than radiotherapy, 3-drugs and supportive care.
__label__noRel	The study underscores the value of undertaking studies in areas of disease prevalence and the necessity of selecting appropriate outcome measures.	Thus, funds permitting, oral Etoposide is a pragmatic approach to treating EKS in an environment where antiretroviral drugs are not universally available.
__label__noRel	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.
__label__Support	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.
__label__noRel	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.
__label__Support	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.
__label__noRel	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.	The overall response rates, which were confirmed by an independent expert panel, were 13% (95% CI, 3.4% to 23.3%), 27% (95% CI, 14.1% to 40.4%), and 40% (95% CI, 25.7% to 54.3%) for arms A, B, and C, respectively.
__label__noRel	Of the three regimens tested, the combination of LV5FU2-irinotecan is the most promising and will be assessed in a phase III trial.	Median progression-free survival and overall survival times were 3.2 months (95% CI, 1.8 to 4.6 months) and 6.8 months (95% CI, 2.6 to 11.1 months) with LV5FU2, respectively; 4.9 months (95% CI, 3.5 to 6.3 months) and 9.5 months (95% CI, 6.9 to 12.2 months) with LV5FU2-cisplatin, respectively; and 6.9 months (95% CI, 5.5 to 8.3 months) and 11.3 months (95% CI, 9.3 to 13.3 months) with LV5FU2-irinotecan, respectively.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__Support	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__noRel	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__Support	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__noRel	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).	Both treatments were well tolerated.
__label__noRel	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__Support	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__noRel	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).	Both treatments were well tolerated.
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.	Both treatments were well tolerated.
__label__noRel	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__noRel	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__noRel	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__Support	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).	Both treatments were well tolerated.
__label__noRel	Both treatments were well tolerated.	A higher percentage of patients receiving the fixed combination had IOP decreases of 2 mm Hg on day 21 relative to baseline compared with latanoprost-treated patients (79.4% vs 51.4%, respectively; P < 0.001).
__label__noRel	Both treatments were well tolerated.	PP analyses found that more patients in the fixed-combination group had IOP decreases >or=3, >or=4, or >or=5 mm Hg (for each target level, P < 0.001 vs latanoprost group) or final IOP 18 mm Hg (fixed -combination, 35.1%; latanoprost, 17.8%; P < 0.001).
__label__noRel	Both treatments were well tolerated.	patients with an inadequate initial IOP response to latanoprost, switching to fixed-combination latanoprosttimolol resulted in a greater decrease in IOP and similar tolerability compared with continuing latanoprost therapy.
__label__noRel	Both treatments were well tolerated.	Similar proportions of patients in the fixed-combination and latanoprost groups reported at least 1 treatment-emergent AE (10.9% and 12.1%, respectively).
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	but the study was not designed to detect differences in these parameters.
__label__noRel	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	Other grade 3/4 toxic effects were rare (<5%).	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	but the study was not designed to detect differences in these parameters.
__label__noRel	Other grade 3/4 toxic effects were rare (<5%).	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	but the study was not designed to detect differences in these parameters.
__label__noRel	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Support	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	but the study was not designed to detect differences in these parameters.
__label__noRel	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	but the study was not designed to detect differences in these parameters.
__label__Support	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	but the study was not designed to detect differences in these parameters.
__label__noRel	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	but the study was not designed to detect differences in these parameters.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	but the study was not designed to detect differences in these parameters.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	but the study was not designed to detect differences in these parameters.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	but the study was not designed to detect differences in these parameters.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	but the study was not designed to detect differences in these parameters.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__Attack	but the study was not designed to detect differences in these parameters.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	but the study was not designed to detect differences in these parameters.	tumor response was shown to have a beneficial effect on QoL indicators.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	The most frequent toxic effects were grade 3/4 diarrhea (arm A: 34%, B: 19%), grade 3/4 neutropenia (A: 5%, B: 19%) and grade 2/3 alopecia (A: 26%, B: 65%).
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Other grade 3/4 toxic effects were rare (<5%).
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Response rates were 34% [95% confidence interval (CI) 20% to 51%] in arm A and 35% (95% CI: 20% to 53%) in arm B.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Median time to progression was 6.9 (4.6-10.1) and 9.2 (7.9-11.5) months and median overall survival was 17.4 (12.6-23.0+) and 24.7 (16.3-26.4+) months.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	Patients with an objective tumor response reported better physical well-being (P < 0.01), mood (P < 0.05), functional performance (P < 0.05) and less effort to cope (P < 0.05) compared with the non-responders and stable disease patients.
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	The 3-weekly irinotecan schedule also seemed advantageous in terms of grade 3/4 diarrhea, time to progression, overall survival and patient convenience,
__label__noRel	tumor response was shown to have a beneficial effect on QoL indicators.	but the study was not designed to detect differences in these parameters.
__label__noRel	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__noRel	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	Response rate, survival, and duration were similar in both arms.
__label__Attack	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__noRel	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	Response rate, survival, and duration were similar in both arms.
__label__Support	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	Response rate, survival, and duration were similar in both arms.
__label__Support	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	Response rate, survival, and duration were similar in both arms.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	Response rate, survival, and duration were similar in both arms.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	Response rate, survival, and duration were similar in both arms.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__Support	Response rate, survival, and duration were similar in both arms.	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	There was significant early attrition due to disease progression; only 61.5% of patients were alive at 2 months.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	There was a significant improvement in KP from baseline to pre-cycle 3 in both arms, with a trend in favor of the 3w4 regimen for duration and faster onset of improvement.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	Eight of the 17 quality-of-life (QOL) variables assessed showed an improvement of more than 10% between baseline and the start of the third cycle of treatment.
__label__noRel	There was no significant difference between the two schedules examined in terms of improvement in KP or QOL, but there seemed to be a trend in favor of the 3w4 schedule.	Response rate, survival, and duration were similar in both arms.
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	hazard ratio was 0.50; P = .0002
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	hazard ratio was 0.42; P = .088.
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	but was controlled with oral medication and did not cause study drug discontinuation.
__label__noRel	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	hazard ratio was 0.50; P = .0002
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	hazard ratio was 0.42; P = .088.
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	hazard ratio was 0.50; P = .0002
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	hazard ratio was 0.42; P = .088.
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	hazard ratio was 0.50; P = .0002	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	hazard ratio was 0.50; P = .0002	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	hazard ratio was 0.50; P = .0002	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.50; P = .0002	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	hazard ratio was 0.50; P = .0002	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.50; P = .0002	hazard ratio was 0.42; P = .088.
__label__noRel	hazard ratio was 0.50; P = .0002	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	hazard ratio was 0.50; P = .0002	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	hazard ratio was 0.50; P = .0002	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	hazard ratio was 0.50; P = .0002
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	hazard ratio was 0.42; P = .088.
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	hazard ratio was 0.50; P = .0002
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	hazard ratio was 0.42; P = .088.
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	hazard ratio was 0.42; P = .088.	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	hazard ratio was 0.42; P = .088.	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	hazard ratio was 0.42; P = .088.	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.42; P = .088.	hazard ratio was 0.50; P = .0002
__label__noRel	hazard ratio was 0.42; P = .088.	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	hazard ratio was 0.42; P = .088.	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	hazard ratio was 0.42; P = .088.	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	hazard ratio was 0.42; P = .088.	but was controlled with oral medication and did not cause study drug discontinuation.
__label__Support	hazard ratio was 0.42; P = .088.	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	hazard ratio was 0.50; P = .0002
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	hazard ratio was 0.42; P = .088.
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	but was controlled with oral medication and did not cause study drug discontinuation.
__label__noRel	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	hazard ratio was 0.50; P = .0002
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	hazard ratio was 0.42; P = .088.
__label__Attack	but was controlled with oral medication and did not cause study drug discontinuation.	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	but was controlled with oral medication and did not cause study drug discontinuation.	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC).
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Median survival was 16.6 months for the FU/LV/bevacizumab group and 12.9 months for the FU/LV/placebo group (hazard ratio, 0.79; P = .16).
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Median progression-free survival was 9.2 months (FU/LV/bevacizumab) and 5.5 months (FU/LV/placebo);
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	hazard ratio was 0.50; P = .0002
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Response rates were 26.0% (FU/LV/bevacizumab) and 15.2% (FU/LV/placebo) (P = .055);
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	duration of response was 9.2 months (FU/LV/bevacizumab) and 6.8 months (FU/LV/placebo);
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	hazard ratio was 0.42; P = .088.
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	Grade 3 hypertension was more common with bevacizumab treatment (16% v 3%)
__label__noRel	Addition of bevacizumab to FU/LV as first-line therapy in CRC patients who were not considered optimal candidates for first-line irinotecan treatment provided clinically significant patient benefit, including statistically significant improvement in progression-free survival.	but was controlled with oral medication and did not cause study drug discontinuation.
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__noRel	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__noRel	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__Support	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__Support	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__Support	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a novel and rational approach to the treatment of cancer cachexia.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	At four weeks, patients who received thalidomide had gained on average 0.37 kg in weight and 1.0 cm(3) in arm muscle mass (AMA) compared with a loss of 2.21 kg (absolute difference -2.59 kg (95% confidence interval (CI) -4.3 to -0.8); p = 0.005) and 4.46 cm(3) (absolute difference -5.6 cm(3) (95% CI -8.9 to -2.2); p = 0.002) in the placebo group.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	At eight weeks, patients in the thalidomide group had lost 0.06 kg in weight and 0.5 cm(3) in AMA compared with a loss of 3.62 kg (absolute difference -3.57 kg (95% CI -6.8 to -0.3); p = 0.034) and 8.4 cm(3) (absolute difference -7.9 cm(3) (95% CI -14.0 to -1.8); p = 0.014) in the placebo group.
__label__noRel	Thalidomide was well tolerated and effective at attenuating loss of weight and lean body mass in patients with cachexia due to advanced pancreatic cancer.	Improvement in physical functioning correlated positively with weight gain (r = 0.56, p = 0.001).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__Support	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__Support	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__noRel	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	AM was associated with higher rates of acute nausea (P = .03), vomiting (P = .007), cardiovascular toxicity (P = .0001), and infection or febrile neutropenia (P = .03).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .9).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	Patient diaries demonstrated lower swallowing dysfunction AUC with amifostine (z test P = .025).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	QOL was not significantly different between the two arms, except for pain, which showed more clinically meaningful improvement and less deterioration at 6 weeks follow-up (v pretreatment) in the AM arm (P = .003).
__label__noRel	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	The median survival rates for both arms were comparable (AM, 17.3 v no AM, 17.9 months; P = .87).
__label__Attack	However, patient self-assessments suggested a possible advantage to AM that is being explored with modified dosing route strategies.	AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfractionated radiation and chemotherapy.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	There was no difference in recovery of food intake among the groups.
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	enteral feeding reduced quality of life most extensively.
__label__Support	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	There was no difference in recovery of food intake among the groups.
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	enteral feeding reduced quality of life most extensively.
__label__Support	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	There was no difference in recovery of food intake among the groups.
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Body weight and whole body fat declined similarly over time in all groups (P < .005),	enteral feeding reduced quality of life most extensively.
__label__Support	Body weight and whole body fat declined similarly over time in all groups (P < .005),	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	There was no difference in recovery of food intake among the groups.
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	lean body mass was unchanged during follow-up compared to preoperative values.	enteral feeding reduced quality of life most extensively.
__label__Support	lean body mass was unchanged during follow-up compared to preoperative values.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	There was no difference in recovery of food intake among the groups.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	enteral feeding reduced quality of life most extensively.
__label__noRel	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	There was no difference in recovery of food intake among the groups.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	There was no difference in recovery of food intake among the groups.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	There was no difference in recovery of food intake among the groups.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	There was no difference in recovery of food intake among the groups.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	There was no difference in recovery of food intake among the groups.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	There was no difference in recovery of food intake among the groups.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	There was no difference in recovery of food intake among the groups.	enteral feeding reduced quality of life most extensively.
__label__Support	There was no difference in recovery of food intake among the groups.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	There was no difference in recovery of food intake among the groups.
__label__noRel	Parenteral feeding was associated with the highest rate of nutrition-related complications,	enteral feeding reduced quality of life most extensively.
__label__Support	Parenteral feeding was associated with the highest rate of nutrition-related complications,	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	enteral feeding reduced quality of life most extensively.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	enteral feeding reduced quality of life most extensively.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	enteral feeding reduced quality of life most extensively.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	enteral feeding reduced quality of life most extensively.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	enteral feeding reduced quality of life most extensively.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	enteral feeding reduced quality of life most extensively.	There was no difference in recovery of food intake among the groups.
__label__noRel	enteral feeding reduced quality of life most extensively.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__Support	enteral feeding reduced quality of life most extensively.	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Survival and hospital stay did not differ among the groups, whereas overall complications were higher on artificial nutrition (P < .05).
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Changes in resting energy expenditure and biochemical tests did not differ during follow-up among the groups.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Body weight and whole body fat declined similarly over time in all groups (P < .005),
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	lean body mass was unchanged during follow-up compared to preoperative values.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Maximum exercise capacity and maximum oxygen consumption were normalized within 6 months postoperatively in all groups.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	There was no difference in recovery of food intake among the groups.
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	Parenteral feeding was associated with the highest rate of nutrition-related complications,
__label__noRel	After major surgery, specialized supportive enteral and parenteral nutrition are not superior to oral nutrition only when guided by a dietitian.	enteral feeding reduced quality of life most extensively.
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	This toxicity profile of GE is similar to GP,
__label__noRel	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	This toxicity profile of GE is similar to GP,
__label__noRel	The rate of grade 2 or above nausea was numerically higher in the GP arm,	but the apparent inferior efficacy may discourage further investigation
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__Attack	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	This toxicity profile of GE is similar to GP,
__label__noRel	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	This toxicity profile of GE is similar to GP,
__label__noRel	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	This toxicity profile of GE is similar to GP,
__label__noRel	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	This toxicity profile of GE is similar to GP,
__label__noRel	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	This toxicity profile of GE is similar to GP,
__label__noRel	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.	but the apparent inferior efficacy may discourage further investigation
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	This toxicity profile of GE is similar to GP,
__label__Support	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.	but the apparent inferior efficacy may discourage further investigation
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	This toxicity profile of GE is similar to GP,
__label__Support	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).	but the apparent inferior efficacy may discourage further investigation
__label__noRel	This toxicity profile of GE is similar to GP,	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	This toxicity profile of GE is similar to GP,	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	This toxicity profile of GE is similar to GP,	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	This toxicity profile of GE is similar to GP,	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	This toxicity profile of GE is similar to GP,	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	This toxicity profile of GE is similar to GP,	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	This toxicity profile of GE is similar to GP,	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	This toxicity profile of GE is similar to GP,	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	This toxicity profile of GE is similar to GP,	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__noRel	This toxicity profile of GE is similar to GP,	but the apparent inferior efficacy may discourage further investigation
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The incidence of WHO grade 3 or 4 anemia, neutropenia and thrombocytopenia was 29, 44 and 22% (GE group), and 28, 49 and 23% (GP group), respectively (p = 0.75, 0.95 and 0.87, respectively).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The rate of grade 2 or above nausea was numerically higher in the GP arm,
__label__noRel	but the apparent inferior efficacy may discourage further investigation	but the difference was not statistically significant (GE 15.5%, GP 27.7%, p = 0.20).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The rate of vomiting in the GE and GP arms was 20.0 and 20.5%, respectively (p = 0.96).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	However, subjective changes in QOL scores on nausea and vomiting were significantly higher in the GP arm (p = 0.001).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	Other symptoms including sore mouth and hair loss were significantly higher in the GE arm (p = 0.003 and 0.007, respectively).
__label__noRel	but the apparent inferior efficacy may discourage further investigation	There were also significant differences observed in emotional (p = 0.014), cognitive (p = 0.028) and social functioning (p = 0.034) in favor of GP.
__label__noRel	but the apparent inferior efficacy may discourage further investigation	The differences in tumor response (35.5 and 46.5% for GE and GP, respectively) were not significantly different.
__label__noRel	but the apparent inferior efficacy may discourage further investigation	Median time to disease progression (33.8 and 40.7 weeks, respectively) and overall survival (41.4 and 57.3 weeks, respectively) were of borderline significance in favor of the GP arm (p = 0.055).
__label__Attack	but the apparent inferior efficacy may discourage further investigation	This toxicity profile of GE is similar to GP,
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__Support	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__Support	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__noRel	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	After the rehabilitation program, cancer survivors (n=63) displayed statistically significant improvements on health-related quality of life with effect sizes (ES) varying from 0.38 to 0.99 (RAND-36) and from -0.34 to -0.57 (RSCL), most persistent at 3-month follow-up.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	Furthermore, statistically significant improvements in exercise capacity and muscle force of upper and lower extremities were displayed after rehabilitation.
__label__noRel	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	A multidimensional rehabilitation program has statistically and clinically relevant beneficial effects on health-related quality of life, exercise capacity, and muscle force in cancer patients with different diagnoses.
__label__Support	If offered a choice, 80% of the patients prior to start and 58% of the patients after completion of the program indicated that they preferred the entire multidimensional program.	if offered the choice, the majority of cancer survivors seem to prefer multidimensional programs to programs with only one component.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	and no significant effects emerged on the secondary end points.
__label__noRel	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	and no significant effects emerged on the secondary end points.
__label__Support	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	No significant main effect of the interventions emerged on cancer-specific distress,	and no significant effects emerged on the secondary end points.
__label__Attack	No significant main effect of the interventions emerged on cancer-specific distress,	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__Attack	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	and no significant effects emerged on the secondary end points.
__label__noRel	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	Between-group differences in the primary outcomes were not significant at 12 months,	and no significant effects emerged on the secondary end points.
__label__Support	Between-group differences in the primary outcomes were not significant at 12 months,	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	and no significant effects emerged on the secondary end points.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	and no significant effects emerged on the secondary end points.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	and no significant effects emerged on the secondary end points.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	and no significant effects emerged on the secondary end points.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__Support	and no significant effects emerged on the secondary end points.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	and no significant effects emerged on the secondary end points.	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	Evidence suggests that the re-entry phase (ie, early period after medical treatment completion) presents distinct challenges for cancer patients.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	In analyses controlling for study site and baseline depressive symptoms, VID produced significant improvement in energy/fatigue at 6 months relative to CTL, particularly among women who felt less prepared for re-entry at baseline.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	No significant main effect of the interventions emerged on cancer-specific distress,
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	but EDU prompted greater reduction in this outcome relative to CTL at 6 months for patients who felt more prepared for re-entry.
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	Between-group differences in the primary outcomes were not significant at 12 months,
__label__noRel	A peer-modeling videotape can accelerate the recovery of energy during the re-entry phase in women treated for breast cancer, particularly among those who feel less prepared for re-entry.	and no significant effects emerged on the secondary end points.
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__Support	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__Support	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__Support	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__Support	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__Support	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	There were significant differences between treatment groups favouring the SNB group throughout the 18 months assessment.
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	Patients in the standard treatment group showed a greater decline in Trial Outcome Index (TOI) scores (physical well-being, functional well-being and breast cancer concerns subscales in FACT-B+4) and recovered more slowly than patients in the SNB group (p < 0.01).
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	The change in total FACT-B+4 scores (measuring global QOL) closely resembled the TOI results.
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	18 months post-surgery approximately twice as many patients in the standard group compared with the SNB group reported substantial arm swelling (14% versus 7%) (p = 0.002) or numbness (19% versus 8.7%) (p < 0.001).
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	there was no evidence of increased anxiety amongst patients randomised to SNB (p > 0.05).
__label__noRel	In view of the benefits regarding arm functioning and quality of life, the data from this randomised study support the use of SNB in patients with clinically node negative breast cancer.	For 6 months post-surgery younger patients reported less favourable QOL scores (p < 0.001) and greater levels of anxiety (p < 0.01).
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Erlotinib was superior to placebo for survival, progression-free survival, and tumor response rate.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Exploratory analyses indicate that epidermal growth factor receptor status may be an important predictor of the erlotinib survival effect.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Rash (75% versus 17%) and diarrhea (54% versus 18%) in the erlotnib and placebo group respectively were the most common adverse events.
__label__noRel	Dose reductions were required for 10% of patients with rash and 4% of patients with diarrhea.	Severe rash occurred in 9% and severe diarrhea in 6% of erlotinib-treated patients and each resulted in study discontinuation in 1% of patients.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Treatments were well tolerated in the 3 groups.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__Support	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Treatments were well tolerated in the 3 groups.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	At a median followup of 26 months we observed 12 biochemical relapses.
__label__Support	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__Support	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Treatments were well tolerated in the 3 groups.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Treatments were well tolerated in the 3 groups.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	No differences in QOL between groups 2 and 3 were found.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	At a median followup of 26 months we observed 12 biochemical relapses.
__label__Support	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Treatments were well tolerated in the 3 groups.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Treatments were well tolerated in the 3 groups.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Treatments were well tolerated in the 3 groups.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Treatments were well tolerated in the 3 groups.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Treatments were well tolerated in the 3 groups.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Treatments were well tolerated in the 3 groups.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Treatments were well tolerated in the 3 groups.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__Support	Treatments were well tolerated in the 3 groups.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Treatments were well tolerated in the 3 groups.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	No differences in QOL between groups 2 and 3 were found.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Treatments were well tolerated in the 3 groups.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	No differences in QOL between groups 2 and 3 were found.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__Support	No differences in QOL between groups 2 and 3 were found.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Treatments were well tolerated in the 3 groups.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	At a median followup of 26 months we observed 12 biochemical relapses.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Treatments were well tolerated in the 3 groups.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Treatments were well tolerated in the 3 groups.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	No differences in QOL between groups 2 and 3 were found.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__noRel	Tamoxifen has been shown to be more effective and safe than RT in this setting.	QOL and sexual function are not negatively influenced by these 2 treatment options
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Of group 1 patients 67% had gynecomastia compared with 8% in group 2 and 34% in group 3.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Breast pain was more frequent in group 1 than in groups 2 and 3 (58% vs 7% and 30%, respectively).
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Differences were significant between groups 1 and 2 (OR 0.12 p <0.001), and groups 1 and 3 (OR 0.52 p < 0.01).
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	In patients in group 1 who had gynecomastia or breast pain a significant decrease in symptoms was achieved in those receiving tamoxifen (p <0.05).
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Treatments were well tolerated in the 3 groups.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	No differences in QOL between groups 2 and 3 were found.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	At a median followup of 26 months we observed 12 biochemical relapses.
__label__noRel	QOL and sexual function are not negatively influenced by these 2 treatment options	Gynecomastia and breast pain induced by bicalutamide monotherapy after RP can be prevented and treated.
__label__Support	QOL and sexual function are not negatively influenced by these 2 treatment options	Tamoxifen has been shown to be more effective and safe than RT in this setting.
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	but the differences tended to disappear in 6 to 12 months.
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__noRel	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__noRel	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	but the differences tended to disappear in 6 to 12 months.
__label__noRel	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__Support	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	but the differences tended to disappear in 6 to 12 months.	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__Attack	but the differences tended to disappear in 6 to 12 months.	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	but the differences tended to disappear in 6 to 12 months.	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__noRel	but the differences tended to disappear in 6 to 12 months.	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__noRel	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	but the differences tended to disappear in 6 to 12 months.
__label__Support	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	Axillary clearance in early breast cancer aims to improve locoregional control and provide staging information
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	In both the patients' subjective assessment of their QL and the physicians' perception of the patients' QL, the largest adverse QL effects of Ax were observed from baseline to the first postoperative assessment,
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	but the differences tended to disappear in 6 to 12 months.
__label__noRel	Avoiding axillary clearance for women > or = 60 years old who have clinically node-negative disease and receive Tam for endocrine-responsive disease yields similar efficacy with better early QL.	At a median follow-up of 6.6 years, results for Sx + Ax and Sx yielded similar DFS (6-year DFS, 67% v 66%; hazard ratio [HR] Sx + Ax/Sx, 1.06; 95% CI, 0.79 to 1.42; P = .69) and OS (6-year OS, 75% v 73%; HR Sx + Ax/Sx, 1.05; 95% CI, 0.76 to 1.46; P = .77).
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__noRel	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__noRel	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	Most of scores indicated less fatigue (higher score) in the standard treatment group,	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	Most of scores indicated less fatigue (higher score) in the standard treatment group,	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__noRel	Most of scores indicated less fatigue (higher score) in the standard treatment group,	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	Most of scores indicated less fatigue (higher score) in the standard treatment group,	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	Most of scores indicated less fatigue (higher score) in the standard treatment group,	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	Most of scores indicated less fatigue (higher score) in the standard treatment group,	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__Attack	Most of scores indicated less fatigue (higher score) in the standard treatment group,	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__noRel	Most of scores indicated less fatigue (higher score) in the standard treatment group,	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__Attack	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__noRel	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__noRel	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__noRel	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__Support	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__noRel	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__noRel	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__Support	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__noRel	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__noRel	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__Support	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__noRel	Clinically, this structured multidisciplinary intervention had no impact on fatigue,	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	Fatigue has a significant impact on the quality of life (QOL) of cancer patients.
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	Recent research has suggested that physical activity can reduce fatigue in patients receiving active cancer treatment.
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	Most of scores indicated less fatigue (higher score) in the standard treatment group,
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	but there were no statistically significant differences found at baseline and weeks 4, 8, and 27 except for SDS at week 8 (P = 0.018) with less patients reporting significant fatigue in the standard treatment arm.
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	For the entire participant population, fatigue levels initially worsened with radiotherapy, stabilized at week 8, and returned to baseline by week 27.
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	Disease site, chemotherapy use, and radiotherapy dose did not have a significant impact on fatigue levels.
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	Radiotherapy initially caused a worsening of fatigue but with time fatigue levels returned to baseline
__label__noRel	there was the suggestion the multiple sessions may have contributed to worse fatigue during active cancer treatment.	Clinically, this structured multidisciplinary intervention had no impact on fatigue,
__label__noRel	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.
__label__noRel	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
__label__noRel	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.	Patients in this study had impaired QOL compared with population norms.
__label__Support	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.
__label__noRel	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.
__label__noRel	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
__label__noRel	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.	Patients in this study had impaired QOL compared with population norms.
__label__Support	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.
__label__noRel	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.
__label__noRel	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.
__label__noRel	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.	Patients in this study had impaired QOL compared with population norms.
__label__Support	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.
__label__noRel	Patients in this study had impaired QOL compared with population norms.	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.
__label__noRel	Patients in this study had impaired QOL compared with population norms.	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.
__label__noRel	Patients in this study had impaired QOL compared with population norms.	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
__label__Attack	Patients in this study had impaired QOL compared with population norms.	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.
__label__noRel	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.	Differences in mean QOL change scores from baseline to study end for epoetin alfa versus BSC were 3.17 points for the FACT-General Total, 9.90 for the FACT-An Fatigue subscale, and 7.30 for the FACT-An Anemia subscale.
__label__noRel	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.	This was equivalent to corrections in QOL deficits attributable to epoetin alfa of 97.3%, 40.7%, and 38.0% for the FACT-General Total, FACT-An Fatigue, and FACT-An Anemia subscale scores, respectively, versus BSC.
__label__noRel	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.	A somewhat greater QOL benefit was observed for the FACT-An Fatigue and FACT-An Anemia subscales in the subset of patients with baseline Hb levels >10.5 g/dl.
__label__noRel	Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl.	Patients in this study had impaired QOL compared with population norms.
__label__noRel	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.
__label__noRel	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.
__label__noRel	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.	QOL declined in patients receiving BSC,
__label__noRel	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.
__label__Support	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.
__label__noRel	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.	This study supports the positive effects of early intervention when analyzed according to initial Hb value.
__label__noRel	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
__label__noRel	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.
__label__noRel	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.	QOL declined in patients receiving BSC,
__label__noRel	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.
__label__Support	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.
__label__noRel	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.	This study supports the positive effects of early intervention when analyzed according to initial Hb value.
__label__noRel	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
__label__noRel	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.
__label__noRel	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.	QOL declined in patients receiving BSC,
__label__noRel	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.
__label__noRel	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.
__label__noRel	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.	This study supports the positive effects of early intervention when analyzed according to initial Hb value.
__label__noRel	QOL declined in patients receiving BSC,	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
__label__noRel	QOL declined in patients receiving BSC,	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.
__label__noRel	QOL declined in patients receiving BSC,	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.
__label__noRel	QOL declined in patients receiving BSC,	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.
__label__noRel	QOL declined in patients receiving BSC,	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.
__label__noRel	QOL declined in patients receiving BSC,	This study supports the positive effects of early intervention when analyzed according to initial Hb value.
__label__noRel	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
__label__noRel	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.
__label__noRel	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.
__label__noRel	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.	QOL declined in patients receiving BSC,
__label__Support	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.
__label__noRel	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.	This study supports the positive effects of early intervention when analyzed according to initial Hb value.
__label__noRel	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
__label__noRel	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.
__label__noRel	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.
__label__noRel	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.	QOL declined in patients receiving BSC,
__label__noRel	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.
__label__Support	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.	This study supports the positive effects of early intervention when analyzed according to initial Hb value.
__label__noRel	This study supports the positive effects of early intervention when analyzed according to initial Hb value.	Significantly fewer EPO patients than BSC patients with initial Hb levels >9.7 g/dl to < or =12.1 g/dl required transfusions.
__label__noRel	This study supports the positive effects of early intervention when analyzed according to initial Hb value.	EPO maintained Hb levels throughout the study for patients with Hb levels >11.3 g/dl to < or =12.1 g/dl, compared with a decrease with BSC.
__label__noRel	This study supports the positive effects of early intervention when analyzed according to initial Hb value.	For patients with baseline Hb levels >10.5 g/dl, for whom the mean changes from baseline to last assessment were measured by the Cancer Linear Analogue Scale assessments of energy and overall QOL as well as by the Functional Assessment of Cancer Therapy (FACT)-Fatigue and FACT-An Anemia subscale, QOL scores were significantly greater with EPO than with BSC.
__label__noRel	This study supports the positive effects of early intervention when analyzed according to initial Hb value.	QOL declined in patients receiving BSC,
__label__noRel	This study supports the positive effects of early intervention when analyzed according to initial Hb value.	the mean decreases in QOL scores were greater for BSC patients with baseline Hb levels >10.5 g/dl, compared with the overall BSC group.
__label__noRel	This study supports the positive effects of early intervention when analyzed according to initial Hb value.	In patients with cancer receiving platinum-based chemotherapy and with baseline Hb levels >10.5 g/dl, early intervention with EPO reduces transfusions, maintains Hb level, and maintains or improves QOL.
__label__noRel	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).
__label__noRel	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).
__label__noRel	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.	There was no statistically difference between the two groups regarding quality of life.
__label__Support	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.
__label__noRel	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.
__label__noRel	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).
__label__noRel	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).	There was no statistically difference between the two groups regarding quality of life.
__label__Support	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.
__label__noRel	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.
__label__noRel	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).
__label__noRel	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).	There was no statistically difference between the two groups regarding quality of life.
__label__Support	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.
__label__noRel	There was no statistically difference between the two groups regarding quality of life.	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.
__label__noRel	There was no statistically difference between the two groups regarding quality of life.	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).
__label__noRel	There was no statistically difference between the two groups regarding quality of life.	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).
__label__Support	There was no statistically difference between the two groups regarding quality of life.	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.
__label__noRel	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.	The response rate was 35.7% vs. 43.8% (P = 0.4), median TTP was 4.7 months vs. 5.5 months (P = 0.6), one-year survival rate was 38.5% vs. 58.6% (P = 0.07) in the NL and NP groups, respectively.
__label__noRel	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.	Grade I-II neuro-sensory toxicity occurred significantly more frequent in NL group than in NP group (68.4% vs. 36.4%, P = 0.0017).
__label__noRel	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.	However, Grade I-II granulocytopenia was significantly less occurred in NL group than in NP group (49.4% vs. 70.6%, P = 0.037).
__label__noRel	Due to good efficacy and tolerability, the NL regimen offered a new candidate for treating advanced NSCLC.	There was no statistically difference between the two groups regarding quality of life.
__label__noRel	Morbidity is an important issue in cancer research.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	Morbidity is an important issue in cancer research.	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	Morbidity is an important issue in cancer research.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	Morbidity is an important issue in cancer research.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	Morbidity is an important issue in cancer research.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	Morbidity is an important issue in cancer research.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	Morbidity is an important issue in cancer research.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__noRel	Morbidity is an important issue in cancer research.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	Morbidity is an important issue in cancer research.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	Morbidity is an important issue in cancer research.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	Morbidity is an important issue in cancer research.
__label__Attack	but like other toxicity scoring systems it has not been formally validated.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	but like other toxicity scoring systems it has not been formally validated.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	Morbidity is an important issue in cancer research.
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__Support	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	Morbidity is an important issue in cancer research.
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	but like other toxicity scoring systems it has not been formally validated.
__label__Support	The conceptually similar endpoints of the two methods correlated significantly.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	The conceptually similar endpoints of the two methods correlated significantly.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	Morbidity is an important issue in cancer research.
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__Support	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	Morbidity is an important issue in cancer research.
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__Support	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	Morbidity is an important issue in cancer research.
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__Support	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	Morbidity is an important issue in cancer research.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__noRel	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	Morbidity is an important issue in cancer research.
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	The observer-based toxicity scoring system used by DAHANCA (the Danish head and neck cancer study group) has proved itself sensitive to differences in toxicity in a large randomised study,
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	but like other toxicity scoring systems it has not been formally validated.
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	The DAHANCA toxicity scoring system and the EORTC QLQ correlated with several clinical endpoints.
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	The conceptually similar endpoints of the two methods correlated significantly.
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	The objective endpoints of the DAHANCA scoring system were only correlated with quality of life endpoints to a very low degree.
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	The DAHANCA toxicity scores had a low sensitivity (0.48-0.74) in detecting equivalent subjective complaints from the questionnaires and the observer-based scoring system severely underestimated patient complaints.
__label__noRel	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	A specific patient group where the DAHANCA score had a higher tendency to fail could not be detected.
__label__Attack	This weakness seems inherent in an observer-based scoring system, and will probably also apply to newer ones like CTCAE 3.0.	The DAHANCA toxicity score is an effective instrument in assessing objective treatment induced toxicity in head and neck cancer patients but insensitive and non-specific with regard to patient assessed subjective endpoints.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.	Different analyses yielded slightly different conclusions
__label__Attack	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).	Different analyses yielded slightly different conclusions
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__Support	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).	Different analyses yielded slightly different conclusions
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__Support	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.	Different analyses yielded slightly different conclusions
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__Support	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.	Different analyses yielded slightly different conclusions
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.	Different analyses yielded slightly different conclusions
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.	Different analyses yielded slightly different conclusions
__label__noRel	Different analyses yielded slightly different conclusions	DPPE (tesmilifene) plus doxorubicin (DOX) demonstrated a significant improvement in survival versus DOX in a phase III clinical trial in advanced breast cancer.
__label__noRel	Different analyses yielded slightly different conclusions	However, DPPE is associated with unusual toxicity in the form of hallucinations, nausea and vomiting which were anticipated to impact on short-term quality of life (QOL).
__label__noRel	Different analyses yielded slightly different conclusions	No statistically significant difference in QOL response between treatment arms was found for any domain or item except nausea and vomiting (P = 0.04).
__label__noRel	Different analyses yielded slightly different conclusions	Cross-sectional comparisons showed statistically significant differences for some domains/items at specific assessment times with all differences favoring the DOX alone arm.
__label__noRel	Different analyses yielded slightly different conclusions	Patients on DPPE/DOX arm were significantly worse in terms of average and median pain change scores.
__label__Attack	Different analyses yielded slightly different conclusions	in general, the QOL analyses were concordant and showed that patients on DOX alone had fewer disease and treatment related adverse events and better QOL.
__label__noRel	Different analyses yielded slightly different conclusions	Interestingly, the QOL response analysis also showed that aggressive premedication regimens appear to ameliorate potential negative effects of DPPE on emesis and nausea as measured by patient assessed QOL.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	Toxicity was mild in both arms.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	QOL analyses favored Arm A.
__label__noRel	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	Toxicity was mild in both arms.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	QOL analyses favored Arm A.
__label__noRel	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	Toxicity was mild in both arms.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	QOL analyses favored Arm A.
__label__noRel	Le(y) is an attractive target since it is expressed by most NSCLC.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	Toxicity was mild in both arms.
__label__noRel	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	QOL analyses favored Arm A.
__label__Support	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	Toxicity was mild in both arms.
__label__noRel	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	QOL analyses favored Arm A.
__label__Support	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	Toxicity was mild in both arms.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	Toxicity was mild in both arms.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	Toxicity was mild in both arms.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	Toxicity was mild in both arms.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	Toxicity was mild in both arms.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	Toxicity was mild in both arms.	QOL analyses favored Arm A.
__label__Support	Toxicity was mild in both arms.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	QOL analyses favored Arm A.	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	QOL analyses favored Arm A.	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	QOL analyses favored Arm A.	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	QOL analyses favored Arm A.	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	QOL analyses favored Arm A.	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	QOL analyses favored Arm A.	Toxicity was mild in both arms.
__label__Support	QOL analyses favored Arm A.	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Chemotherapy prolongs survival and improves quality of life (QOL) for good performance status (PS) patients with advanced non-small cell lung cancer (NSCLC).
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Targeted therapies may improve chemotherapy effectiveness without worsening toxicity.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Le(y) is an attractive target since it is expressed by most NSCLC.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	SGN-15 was active against Le(y)-positive tumors in early phase clinical trials and was synergistic with docetaxel in preclinical experiments.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Patients on Arms A and B had median survivals of 31.4 and 25.3 weeks, 12-month survivals of 29% and 24%, and 18-month survivals of 18% and 8%, respectively
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	Toxicity was mild in both arms.
__label__noRel	SGN-15 plus docetaxel is a well-tolerated and active second and third line treatment for NSCLC patients	QOL analyses favored Arm A.
__label__noRel	There was a significant decrease in pad use in group A.	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	There was a significant decrease in pad use in group A.	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	There was a significant decrease in pad use in group A.	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__noRel	There was a significant decrease in pad use in group A.	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	There was a significant decrease in pad use in group A.	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	There was a significant decrease in pad use in group A.
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__Support	After 16 wk, 39 patients versus 27 were dry (p=0.007).	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	After 16 wk, 39 patients versus 27 were dry (p=0.007).	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	There was a significant decrease in pad use in group A.
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__Support	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	There was a significant decrease in pad use in group A.
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__Support	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	There was a significant decrease in pad use in group A.
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__Support	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	There was a significant decrease in pad use in group A.
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	After 16 wk, 39 patients versus 27 were dry (p=0.007).
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	At 20 wk, 4 wk after planned interruption of duloxetine, we observed a U-turn, 23 patients were completely dry in group A versus 38 in group B (p=0.008).
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	Whereas, after 24 wk, 31 in group A versus 41 in group B were dry (p=0.08)
__label__noRel	The data suggest that combination therapy might provide another treatment option for SUI in men that might increase the percentage of early postsurgery continence.	The decrease in IEF and improvements in I-QoL scores were significantly greater in group A for the first 16 wk.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__Support	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	There were no statistically significant differences between treatment groups in ES total scores.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__Support	There were no statistically significant differences between treatment groups in ES total scores.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	there were differences between treatment groups in patient-reported side effects:	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	There were no statistically significant differences between treatment groups in ES total scores.
__label__Support	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	There were no statistically significant differences between treatment groups in ES total scores.
__label__Support	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	There were no statistically significant differences between treatment groups in ES total scores.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	there were differences between treatment groups in patient-reported side effects:
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen.
__label__noRel	In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.	Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Two-year survival rate was 18% with DCF and 9% with CF.	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Two-year survival rate was 18% with DCF and 9% with CF.	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Overall response rate was higher with DCF (chi2 P = .01).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Overall response rate was higher with DCF (chi2 P = .01).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__Support	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__Support	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Overall survival was longer with DCF versus CF (23% risk reduction; log-rank P = .02).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Two-year survival rate was 18% with DCF and 9% with CF.
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Overall response rate was higher with DCF (chi2 P = .01).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Grade 3 to 4 treatment-related adverse events occurred in 69% (DCF) v 59% (CF) of patients.
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Frequent grade 3 to 4 toxicities for DCF v CF were: neutropenia (82% v 57%), stomatitis (21% v 27%), diarrhea (19% v 8%), lethargy (19% v 14%).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Complicated neutropenia was more frequent with DCF than CF (29% v 12%).
__label__noRel	Incorporation of docetaxel, as in DCF or with other active drug(s), is a new therapy option for patients with untreated advanced gastric cancer.	Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity.
__label__noRel	There was no difference in any outcome between groups.	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	There was no difference in any outcome between groups.	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	There was no difference in any outcome between groups.	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	There was no difference in any outcome between groups.	Stretching is an effective technique for increasing range of motion,
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	There was no difference in any outcome between groups.
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.	Stretching is an effective technique for increasing range of motion,
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	There was no difference in any outcome between groups.
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	The incidence of lymphedema during the study was low for both groups and did not differ between groups.	Stretching is an effective technique for increasing range of motion,
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	There was no difference in any outcome between groups.
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.	Stretching is an effective technique for increasing range of motion,
__label__noRel	Stretching is an effective technique for increasing range of motion,	There was no difference in any outcome between groups.
__label__noRel	Stretching is an effective technique for increasing range of motion,	Breast symptoms increased for both groups during radiotherapy, without loss of strength or range of movement.
__label__noRel	Stretching is an effective technique for increasing range of motion,	The incidence of lymphedema during the study was low for both groups and did not differ between groups.
__label__noRel	Stretching is an effective technique for increasing range of motion,	The pectoral stretching program did not influence the outcomes measured because the symptoms reported by patients were not a consequence of contracture.
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__Support	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__Support	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__Support	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	Functional outcome, QOL, and morbidity are similar for the two approaches.	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	There were no differences in functional outcome, morbidity, or QOL between LRP and ORP.
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	The body image and cosmesis scores of female patients were significantly higher in the LRP group than in the ORP group (body image, 17.4 vs 14.9; cosmesis, 19.1 vs 13.0, respectively).
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	The female patients in the ORP group had significantly lower body image scores than the male patients (14.9 vs 18.3).
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	This study is the first to show that ORP has a negative impact on body image and cosmesis as compared with LRP.
__label__noRel	The advantages of a long-lasting improved body image and cosmesis for this relatively young patient population may compensate for the longer operating times and higher costs, particularly for women.	Functional outcome, QOL, and morbidity are similar for the two approaches.
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__noRel	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__Support	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__noRel	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__Attack	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__Support	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer.
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	Sertraline had no significant effect (scale, benefit over placebo [95% CI]) on depression (CES-D 0.4 [-2.6 to 3.4]), anxiety (HADS-A 2.0 [-1.5 to 5.5]), fatigue (FACT-F 0.3 [-4.3 to 4.9]), overall quality of life (FACT-G 1.7 [-1.3 to 4.7]), or clinicians' ratings (SQLI 2.0 [-2.5 to 6.5]), and the 95% CI ruled out a clinically significant benefit for all main outcomes.
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	Sertraline was discontinued more often and earlier than was placebo (hazard ratio 1.46 [1.03-2.06], p=0.03).
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	the first planned interim analysis in February 2006 (n=150) showed that survival was longer in patients assigned placebo than in patients assigned sertraline (unadjusted hazard ratio 1.60 [95% CI 1.04-2.45], log-rank p=0.04; adjusted hazard ratio 1.62 [1.06-2.41], Cox model p=0.02).
__label__noRel	Sertraline did not improve symptoms, wellbeing, or survival in patients with advanced cancer who do not have major depression, and should be reserved for those with a proven indication.	However, at the final analysis in July 2006 of all patients (n=189) and with longer follow-up, survival did not differ significantly between the treatment groups (unadjusted hazard ratio 1.35 [0.95-1.91], log-rank p=0.09; adjusted hazard ratio 1.27 [0.87-1.84], Cox model p=0.20).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The quality of life was almost the same between the arms
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The quality of life was almost the same between the arms
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The quality of life was almost the same between the arms
__label__Support	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The quality of life was almost the same between the arms
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__Support	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The quality of life was almost the same between the arms
__label__Support	Grades 3/4 toxicities occurred infrequently in both arms.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The quality of life was almost the same between the arms	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The quality of life was almost the same between the arms	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The quality of life was almost the same between the arms	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The quality of life was almost the same between the arms	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The quality of life was almost the same between the arms	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The quality of life was almost the same between the arms	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The quality of life was almost the same between the arms	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The quality of life was almost the same between the arms
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The quality of life was almost the same between the arms
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__Support	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	When combined hormone therapy (n=2196) was compared with placebo (n=2189), there was a significant increase in the number of major cardiovascular events (7 v 0, P=0.016) and venous thromboembolisms (22 v 3, hazard ratio 7.36 (95% CI 2.20 to 24.60)).
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	There were no statistically significant differences in numbers of breast or other cancers (22 v 25, hazard ratio 0.88 (0.49 to 1.56)), cerebrovascular events (14 v 19, 0.73 (0.37 to 1.46)), fractures (40 v 58, 0.69 (0.46 to 1.03)), and overall deaths (8 v 5, 1.60 (0.52 to 4.89)).
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	Comparison of combined hormone therapy (n=815) versus oestrogen therapy (n=826) outcomes revealed no significant differences.
__label__Attack	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	Hormone replacement therapy increases cardiovascular and thromboembolic risk when started many years after the menopause.
__label__noRel	Research is needed to assess the long term risks and benefits of starting hormone replacement therapy near the menopause, when the effect may be different.	The results are consistent with the findings of the women's health initiative study and secondary prevention studies.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	No decrease in fatigue-related distress was detected.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	No decrease in fatigue-related distress was detected.
__label__Support	The intervention demonstrated a trend toward improved CRF,	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__Attack	although this effect was reduced once confounders had been controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	No decrease in fatigue-related distress was detected.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	No decrease in fatigue-related distress was detected.
__label__Support	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	No decrease in fatigue-related distress was detected.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	No decrease in fatigue-related distress was detected.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	No decrease in fatigue-related distress was detected.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	No decrease in fatigue-related distress was detected.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__Support	No decrease in fatigue-related distress was detected.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	No decrease in fatigue-related distress was detected.
__label__noRel	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.
__label__noRel	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
__label__noRel	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).
__label__noRel	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
__label__noRel	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.	Infection rates were negligible in both groups.
__label__noRel	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.
__label__noRel	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.
__label__noRel	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
__label__noRel	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
__label__noRel	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).
__label__noRel	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
__label__noRel	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.	Infection rates were negligible in both groups.
__label__noRel	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.
__label__Support	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.
__label__noRel	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
__label__noRel	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.
__label__noRel	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).
__label__noRel	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
__label__noRel	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.	Infection rates were negligible in both groups.
__label__noRel	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.
__label__Support	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.
__label__noRel	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
__label__noRel	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.
__label__noRel	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
__label__noRel	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
__label__noRel	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).	Infection rates were negligible in both groups.
__label__noRel	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.
__label__noRel	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.
__label__noRel	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
__label__noRel	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.
__label__noRel	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
__label__noRel	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).
__label__noRel	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).	Infection rates were negligible in both groups.
__label__noRel	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.
__label__noRel	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.
__label__noRel	Infection rates were negligible in both groups.	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
__label__noRel	Infection rates were negligible in both groups.	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.
__label__noRel	Infection rates were negligible in both groups.	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
__label__noRel	Infection rates were negligible in both groups.	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).
__label__noRel	Infection rates were negligible in both groups.	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
__label__noRel	Infection rates were negligible in both groups.	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.
__label__noRel	Infection rates were negligible in both groups.	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.
__label__noRel	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
__label__noRel	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.
__label__noRel	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
__label__noRel	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).
__label__noRel	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
__label__noRel	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.	Infection rates were negligible in both groups.
__label__noRel	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.
__label__noRel	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.	Tumor necrosis factor-alpha (TNF-alpha) is a putative mediator of the cancer anorexia/weight loss syndrome.
__label__noRel	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.	Over time, weight gain was found to be minimal in both treatment arms; no patient gained >or=10% of their baseline weight.
__label__noRel	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.	Previously validated appetite questionnaires revealed negligible improvements in both treatment arms.
__label__noRel	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.	The median survival was also comparable (175 days vs 148 days in etanercept-treated and placebo-exposed patients, respectively; P = .82).
__label__noRel	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.	preliminary data regarding adverse events demonstrated that patients treated with etanercept had higher rates of neurotoxicity (29% vs 0%) but lower rates of anemia (0% vs 19%) and thrombocytopenia (0% vs 14%).
__label__noRel	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.	Infection rates were negligible in both groups.
__label__noRel	Etanercept, as prescribed in the current trial, does not appear to palliate the cancer anorexia/weight loss syndrome in patients with advanced disease.	Genotyping for TNF-alpha-238 and TNF-alpha-308 polymorphisms revealed no clinical significance for these genotypes, except for a preliminary association between presence of the -238 G/A genotype and relatively less favorable survival.
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	QW epoetin-alpha was found to be well tolerated.
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__noRel	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	QW epoetin-alpha was found to be well tolerated.
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__noRel	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	QW epoetin-alpha was found to be well tolerated.
__label__Support	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__noRel	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	QW epoetin-alpha was found to be well tolerated.
__label__Support	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__noRel	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	QW epoetin-alpha was found to be well tolerated.
__label__Support	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__noRel	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	QW epoetin-alpha was found to be well tolerated.
__label__Support	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__noRel	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	QW epoetin-alpha was found to be well tolerated.	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	QW epoetin-alpha was found to be well tolerated.	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	QW epoetin-alpha was found to be well tolerated.	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	QW epoetin-alpha was found to be well tolerated.	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	QW epoetin-alpha was found to be well tolerated.	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	QW epoetin-alpha was found to be well tolerated.	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	QW epoetin-alpha was found to be well tolerated.	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__Support	QW epoetin-alpha was found to be well tolerated.	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	QW epoetin-alpha was found to be well tolerated.
__label__Support	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	Patients receiving chemotherapy for cancer often develop anemia, which can contribute to increased morbidity and reduced quality of life (QOL).
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	Chemotherapy-induced anemia can be successfully treated using recombinant human erythropoietin (rHuEPO).
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	Among the 30 patients evaluable for hematologic response, the mean increase in Hb from baseline to time of final evaluation was 3.08 +/- 1.48 g/dl (p < 0.001).
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	An increase in Hb of > or = 2 g/dl, in the absence of blood transfusion, occurred in 70% of patients (21 of 30 patients) who were on the study for > or = 30 days.
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	The overall response rate (Hb increase > or = 2 g/dl or Hb > or = 12 g/dl in the absence of blood transfusion) was 90% (27 of 30 patients).
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	In 30 patients who were evaluable for QOL assessment, epoetin-alpha therapy was found to significantly (p < 0.001) improve mean cancer linear analog scale (CLAS) scores for energy level, ability to perform daily activity, and overall QOL from baseline to the time of final evaluation.
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	QW epoetin-alpha was found to be well tolerated.
__label__noRel	The once-weekly schedule is convenient, safe, and may reduce the burden on patients, parents, and their caregivers by reducing the number of visits to the clinic.	Treatment with QW epoetin-alpha was found to increase Hb levels, decrease transfusion requirement, and improve functional status and QOL in anemic patients with ALL in maintenance receiving chemotherapy.
__label__noRel	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.
__label__noRel	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.
__label__noRel	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.
__label__Support	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.
__label__noRel	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.	Women with breast cancer may have an even higher risk of depression particularly in a postmenopausal or estrogen deficiency state.
__label__noRel	An antidepressant should be considered for early stage breast cancer patients with depressive symptoms who are receiving adjuvant treatment.	The use of fluoxetine for 6 months resulted in an improvement in quality of life, a higher completion of adjuvant treatment (chemotherapy, hormonal therapy, chemotherapy plus hormonal therapy), and a reduction in depressive symptoms compared to patients who received placebo.
__label__noRel	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__noRel	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__noRel	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	HDC has a negative impact on QOL even after treatment phase.
__label__Support	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__Support	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	HDC has a negative impact on QOL even after treatment phase.
__label__noRel	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__Support	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	HDC has a negative impact on QOL even after treatment phase.
__label__noRel	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__noRel	HDC has a negative impact on QOL even after treatment phase.	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.
__label__noRel	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	This negative impact tended to last longer in the HDC group, as for most of the QLQ-C30 scales, the QOL scores of HDC patients tend to improve at a slower rate than that of patients receiving standard chemotherapy.
__label__noRel	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	physical functioning remains deteriorated 1 year after inclusion for HDC patients comparatively to conventional chemotherapy patients (85.99 vs. 76.65, P = 0.021)
__label__noRel	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	and the pain score was still higher in the HDC group at that time (28.32 vs. 15.97, P = 0.004).
__label__Support	Toxicity of HDC has a strong negative impact on patients' QOL during the treatment phase.	HDC has a negative impact on QOL even after treatment phase.
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	although the P value was of borderline statistical significance (P = .048).
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	although the P value was of borderline statistical significance (P = .048).
__label__noRel	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__Support	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__Attack	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	although the P value was of borderline statistical significance (P = .048).
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	although the P value was of borderline statistical significance (P = .048).	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	although the P value was of borderline statistical significance (P = .048).	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__Attack	although the P value was of borderline statistical significance (P = .048).	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	although the P value was of borderline statistical significance (P = .048).	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	although the P value was of borderline statistical significance (P = .048).	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	although the P value was of borderline statistical significance (P = .048).
__label__noRel	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	The overall response rate was 16% in the PLD arm compared with 29% in the GEM arm (P = .056).
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	No statistically significant difference in time to progression (TTP) curves according to treatment allocation was documented (P = .411).
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	However, a trend for more favorable overall survival was documented in the PLD arm compared with the GEM arm,
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	although the P value was of borderline statistical significance (P = .048).
__label__noRel	GEM does not provide an advantage compared with PLD in terms of TTP in ovarian cancer patients who experience recurrence within 12 months after primary treatment but should be considered in the spectrum of drugs to be possibly used in the salvage setting.	Statistically significantly higher global QOL scores were found in PLD-treated patients at the first and second postbaseline QOL assessments.
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).
__label__Support	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	For treatment of advanced breast cancer, SFI can alleviate the bone marrow inhibition caused by chemotherapy, improve clinical symptoms and quality of life and prolong the survival period by regulating cellular immune function of patients, so as to enhance the therapeutic effect of chemotherapy.
__label__noRel	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	The level of CD3+ CD4+ and CD4+/CD8+ ratio increased (P < 0.05) and CD8+ decreased in the treatment group (P < 0.01), while they showed insignificant change in the control group.
__label__noRel	The total short-term remission rate, the improvement rate of clinical syndrome and quality of life was 50.0%, 70.0% and 76.7% in the treatment group, and 43.3%, 46.7% and 50.0% in the control group, respectively, showing significant difference between the two groups (all P < 0.05).	The occurrence of adverse reaction in the treatment group was lower than that in the control group (P < 0.05).
__label__noRel	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__noRel	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__Support	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__noRel	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__Support	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__Support	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__Support	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	The KPS score in the treated group after treatment was improved in 13 patients (23.6%), stabilized in 27 (49.6%) and declined in 15 (27.3%), while in the control group, it was improved in 7 (13.2%), stabilized in 21 (39.6%) and declined in 25 (47.2%), the difference between the two groups was significant (P < 0.05).
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	The results from evaluation with QLQ-C30 questionnaire and LC30 scale in the treated group was also superior to those in the control group (P < 0.05), respectively.
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	The scores of TCM efficacy (24.52 +/- 8.98 vs 29.76 +/- 7.09, P < 0.05) and the 6-min walking distance (233.4 +/- 29.2 m vs 205.8 +/- 31.9 m, P < 0.05) were better in the treated group.
__label__noRel	TCM therapy for removing toxic substance and unblocking meridians can improve the post-radiation QOL of patients with lung cancer to some extent.	After treatment in the treated group, the body weight was increased in 11 patients (20.0%), stabilized in 28 (50.9%) and decreased in 16 (29.1%), while in the control group it was increased in 5 (9.4%), stabilized in 26 (49.1%) and decreased in 22 (41.5%), difference between the two groups was significant, too (P < 0.05).
__label__noRel	Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).	Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).
__label__noRel	Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).	Patients under combined treatment were at higher risk of severe thrombocytopenia.
__label__Support	Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).	Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.
__label__noRel	Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).	Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).
__label__noRel	Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).	Patients under combined treatment were at higher risk of severe thrombocytopenia.
__label__noRel	Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).	Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.
__label__noRel	Patients under combined treatment were at higher risk of severe thrombocytopenia.	Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).
__label__noRel	Patients under combined treatment were at higher risk of severe thrombocytopenia.	Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).
__label__noRel	Patients under combined treatment were at higher risk of severe thrombocytopenia.	Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.
__label__noRel	Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.	Median overall survival was 17.2 months (95% CI, 13.5 to 21.9 months) with topotecan, 17.8 months (95% CI, 13.7 to 20.0 months) with topotecan plus etoposide (log-rank P = .7647), and 15.2 months (95% CI, 11.3 to 20.9 months) with topotecan plus gemcitabine (log-rank P = .2344).
__label__noRel	Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.	Platinum-sensitive patients lived significantly longer than platinum-refractory patients (21.9 v 10.6 months).
__label__noRel	Nonplatinum topotecan combinations do not provide a survival advantage over topotecan alone in women with relapsed ovarian cancer.	Patients under combined treatment were at higher risk of severe thrombocytopenia.
__label__noRel	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).
__label__Support	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.
__label__noRel	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).
__label__Support	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.
__label__noRel	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.	The mean IOP in the first period when all patients were dosed in the evening was assessed 12 h after dosing at 09:00 and it was similar in the two treatment groups (mean +/- standard deviation: 17.9 +/- 2.7 mmHg for travoprost versus 17.7 +/- 2.5 mmHg for latanoprost, p = 0.812).
__label__noRel	a.m.-dosed travoprost is superior to a.m.-dosed latanoprost by 1.7 mmHg at 24-h post-dose.	In the a.m.-dosing crossover comparison, the 24-h post-dose IOP was significantly lower ( p < 0.001) on travoprost (16.9 +/- 3.1 mmHg) compared to latanoprost (18.6 +/- 3.3 mmHg).
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.	There were no opportunistic infections.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.	There were no opportunistic infections.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__Support	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).	There were no opportunistic infections.
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__Support	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.	There were no opportunistic infections.
__label__Support	There were no opportunistic infections.	Abatacept demonstrated acceptable safety and tolerability and clinically meaningful efficacy over 6 months in patients with inadequate response to anti-TNF therapy.
__label__noRel	There were no opportunistic infections.	Results were comparable with or without a washout, supporting direct switching from anti-TNF therapy to abatacept as an option in clinical practice.
__label__noRel	There were no opportunistic infections.	At 6 months, in washout versus direct-switch patients, similar clinically meaningful improvements were seen in DAS28 (CRP) (> or =1.2 unit improvement, 59.5% vs 53.6%, respectively; low disease activity state, 22.5% vs 22.3%; DAS28-defined remission, 12.0% vs 13.7%), physical function (health assessment questionnaire disability index > or =0.22 improvement; 46.3% vs 47.1%) and health-related quality of life (mean change in short-form 36 scores: physical component summary, 5.5 vs 6.1; mental component summary, 4.8 vs 5.4).
__label__noRel	There were no opportunistic infections.	At 6 months, adverse events (AE; 78.0% vs 79.2%), serious AE (11.1% vs 9.9%) and discontinuations due to AE (3.8% vs 4.0%) and serious AE (2.0% vs 1.3%) were comparable in washout versus direct-switch patients.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	No unexpected adverse events were observed,
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__Support	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	No unexpected adverse events were observed,
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__Support	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	No unexpected adverse events were observed,	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	No unexpected adverse events were observed,	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	No unexpected adverse events were observed,	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	No unexpected adverse events were observed,	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__Support	No unexpected adverse events were observed,	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	No unexpected adverse events were observed,	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	No unexpected adverse events were observed,
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__Support	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	No unexpected adverse events were observed,
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	No unexpected adverse events were observed,
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	Neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate (hazard ratio [HR], 1.22; 95% CI, 0.95 to 1.57; P = .12; and HR, 1.12; 95% CI, 0.87 to 1.43; P = .39, respectively).
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	In the gefitinib 250 mg/day, 500 mg/day, and methotrexate groups, respectively, median overall survival was 5.6, 6.0, and 6.7 months; ORRs (Response Evaluation Criteria in Solid Tumors) were 2.7%, 7.6% and 3.9%, with no statistically significant difference between either gefitinib arm and methotrexate.
__label__Attack	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	No unexpected adverse events were observed,
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	QOL improvement rates (Functional Assessment of Cancer Therapy-Head &amp; Neck total score) were 13.4%, 18.0%, and 6.0% for gefitinib 250 mg/day, 500 mg/day, and methotrexate, respectively.
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	In patients with recurrent or metastatic SCCHN, while responses with gefitinib were seen, neither gefitinib 250 nor 500 mg/day improved overall survival compared with methotrexate.
__label__noRel	except for tumor hemorrhage-type events with gefitinib (8.9%, gefitinib 250 mg/day; 11.4%, gefitinib 500 mg/day; 1.9%, methotrexate).	With the exception of tumor hemorrhage-type events with gefitinib, the adverse event profiles were generally consistent with those previously observed.
__label__noRel	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.
__label__Support	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
__label__noRel	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.
__label__noRel	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.
__label__Support	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
__label__noRel	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.
__label__noRel	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.
__label__noRel	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.
__label__noRel	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.
__label__noRel	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.	For the chemotherapy group, the mean Quality Adjusted Life Months over 24 months (QALM-24) was 9.6 (95% CI: 8.7, 11.2) months compared with the mean QALM-24 of 8.6 (95% CI: 7.6, 10.5) months for the no chemotherapy group.
__label__noRel	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.	For the chemoradiation group, the mean QALM-24 was 7.1 (95% CI: 6.0, 9.0) months compared with the mean QALM-24 of 8.1 (95% CI: 7.0, 10.0) months for the no chemoradiation group.
__label__noRel	The previously reported survival advantage supporting the use of adjuvant chemotherapy is maintained when adjusted using quality adjusted survival methodology.	Chemotherapy provided on average an additional 1.0 quality-adjusted life months within a restricted 2-year time period from the time of resection.
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__Support	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).	Adverse events were mild in both groups;
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__noRel	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Both drugs were well tolerated with mild ocular adverse events.
__label__Attack	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).	Adverse events were mild in both groups;
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__Support	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).	Adverse events were mild in both groups;
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.	Adverse events were mild in both groups;
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__noRel	Both drugs were well tolerated with mild ocular adverse events.	Adverse events were mild in both groups;
__label__noRel	Adverse events were mild in both groups;	Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23).
__label__noRel	Adverse events were mild in both groups;	however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01).
__label__noRel	Adverse events were mild in both groups;	22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).
__label__noRel	Adverse events were mild in both groups;	Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG.
__label__Support	Adverse events were mild in both groups;	Both drugs were well tolerated with mild ocular adverse events.
__label__noRel	Baseline characteristics were comparable for both groups,	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	Baseline characteristics were comparable for both groups,	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	Baseline characteristics were comparable for both groups,	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	Baseline characteristics were comparable for both groups,	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	Baseline characteristics were comparable for both groups,	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__Attack	except that more patients with ADPKD were assigned to the placebo group (P = .03).	Baseline characteristics were comparable for both groups,
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	except that more patients with ADPKD were assigned to the placebo group (P = .03).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	Baseline characteristics were comparable for both groups,
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__Support	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	Baseline characteristics were comparable for both groups,
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__Support	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	Baseline characteristics were comparable for both groups,
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__Support	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	Baseline characteristics were comparable for both groups,
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	except that more patients with ADPKD were assigned to the placebo group (P = .03).
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	The mean liver volume decreased 2.9%, from 4606 mL (95% confidence interval (CI): 547-8665) to 4471 mL (95% CI: 542-8401 mL), in patients given lanreotide.
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	In the placebo group, the mean liver volume increased 1.6%, from 4689 mL (95% CI: 613-8765 mL) to 4895 mL (95% CI: 739-9053 mL) (P < .01).
__label__noRel	In patients with polycystic liver, 6 months of treatment with lanreotide reduces liver volume.	Post hoc stratification for patients with ADPKD or PCLD revealed similar changes in liver volume, with statistically significant differences in patients given lanreotide (P < .01 for both diseases).
__label__noRel	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__Support	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__Support	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__noRel	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__Support	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).
__label__noRel	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	Hospital stay for patients who received EOF (n=71) was 4.7 vs. 5.8 days for the TOF group (n=72) (P=0.006).
__label__noRel	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	The mean level of postoperative satisfaction was significantly higher in the EOF group (82.8 vs. 71.7 mm, P B 0.001).
__label__Support	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	On the basis of these findings, the policy of EOF should be used after a complex gynecologic oncologic laparotomy.
__label__noRel	Patients who received the TOF scheme had significantly higher overall postoperative complications (39 vs. 17% in EOF group, P=0.003) and infective complications (14% in TOF group vs. 3% in EOF group, P=0.017).	Variables such as nausea and vomiting, analgesic and antiemetic requirement as well as level of pain and quality of life were not different between groups.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	Despite slow initial symptom improvement,
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__Support	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	Because stent placement was associated with better short-term outcomes,
__label__noRel	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Despite slow initial symptom improvement,
__label__Support	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	Because stent placement was associated with better short-term outcomes,
__label__noRel	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Despite slow initial symptom improvement,
__label__Support	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	Because stent placement was associated with better short-term outcomes,
__label__noRel	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Despite slow initial symptom improvement,
__label__Support	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	Because stent placement was associated with better short-term outcomes,
__label__noRel	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Despite slow initial symptom improvement,
__label__Support	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	Because stent placement was associated with better short-term outcomes,
__label__noRel	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	Despite slow initial symptom improvement,
__label__Support	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	Because stent placement was associated with better short-term outcomes,
__label__noRel	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	Despite slow initial symptom improvement,	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	Despite slow initial symptom improvement,	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Despite slow initial symptom improvement,	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Despite slow initial symptom improvement,	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Despite slow initial symptom improvement,	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Despite slow initial symptom improvement,	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__Attack	Despite slow initial symptom improvement,	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	Despite slow initial symptom improvement,	Because stent placement was associated with better short-term outcomes,
__label__noRel	Despite slow initial symptom improvement,	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Despite slow initial symptom improvement,
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	Because stent placement was associated with better short-term outcomes,
__label__noRel	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	Because stent placement was associated with better short-term outcomes,	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	Because stent placement was associated with better short-term outcomes,	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	Because stent placement was associated with better short-term outcomes,	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	Because stent placement was associated with better short-term outcomes,	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	Because stent placement was associated with better short-term outcomes,	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	Because stent placement was associated with better short-term outcomes,	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	Because stent placement was associated with better short-term outcomes,	Despite slow initial symptom improvement,
__label__noRel	Because stent placement was associated with better short-term outcomes,	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__Support	Because stent placement was associated with better short-term outcomes,	this treatment is preferable for patients expected to live less than 2 months.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Food intake improved more rapidly after stent placement than after GJJ (GOO Scoring System score > or = 2: median 5 vs 8 days, respectively; P < .01)
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	but long-term relief was better after GJJ, with more patients living more days with a GOO Scoring System score of 2 or more than after stent placement (72 vs 50 days, respectively; P = .05).
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	More major complications (stent: 6 in 4 patients vs GJJ: 0; P = .02), recurrent obstructive symptoms (stent: 8 in 5 patients vs GJJ: 1 in 1 patient; P = .02), and reinterventions (stent: 10 in 7 patients vs GJJ: 2 in 2 patients; P < .01) were observed after stent placement compared with GJJ.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	When stent obstruction was not regarded as a major complication, no differences in complications were found (P = .4).
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	There were also no differences in median survival (stent: 56 days vs GJJ: 78 days) and quality of life.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Mean total costs of GJJ were higher compared with stent placement ($16,535 vs $11,720, respectively; P = .049 [comparing medians]).
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Despite slow initial symptom improvement,
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	GJJ was associated with better long-term results and is therefore the treatment of choice in patients with a life expectancy of 2 months or longer.
__label__noRel	this treatment is preferable for patients expected to live less than 2 months.	Because stent placement was associated with better short-term outcomes,
__label__noRel	Results were correlated with previously reported objective sensibility outcomes.	There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.
__label__Support	Results were correlated with previously reported objective sensibility outcomes.	This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.
__label__noRel	There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.	Results were correlated with previously reported objective sensibility outcomes.
__label__Support	There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.	This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.
__label__noRel	This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.	Results were correlated with previously reported objective sensibility outcomes.
__label__noRel	This study demonstrates that innervation of free TRAM flaps used for breast reconstruction not only improves sensibility but also has a positive effect on patient-rated quality of life.	There was a statistically significant improvement in all three measures in patients who were randomized to receive innervated free TRAM flaps compared with those receiving noninnervated flaps.
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__Support	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__noRel	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__Support	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	Transient grade 4 neutropenia occurred in 18 and 2 patients, and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively.
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	The PSA response rates were 50% and 23%, measurable disease response rates (CR+PR) 14% and 15%, and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively.
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9/10 (.71 s.d.), and a significantly lower level of QOL than Arm A (p = 0.01).
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	As hypothesized, Bcl-2 levels decreased with CRA/IFN therapy only in Arm B (p = 0.03).
__label__noRel	Given the adverse effect of CRA/IFN/TAX on QOL, the study of other novel agents that target Bcl-2 family proteins is warranted.	Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC.
__label__Support	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;
__label__noRel	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).
__label__noRel	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;
__label__noRel	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).
__label__noRel	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).
__label__noRel	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;
__label__noRel	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).
__label__Support	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;
__label__noRel	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;
__label__noRel	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;	At 15 months, the mean number of medications was lower in the combined group than in the control group (0.4 +/- 0.7 and 1.3 +/- 1.0, respectively; P = .007), as was the proportion of patients on ocular hypotensive medication (33% and 76%, respectively).
__label__Support	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;	Phacoemulsification with stent implantation was more effective in controlling IOP than phacoemulsification alone;
__label__noRel	The mean IOP was 14.8 +/- 1.2 mm Hg in the combined group and 15.7 +/- 1.1 mm Hg in the control group at 15 months and 16.6 +/- 3.1 mm Hg and 19.2 +/- 3.5 mm Hg, respectively, after washout;	the IOP was statistically significantly lower in the combined group than in the control group at both time points (P = .031 and P = .042, respectively).
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__noRel	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__Support	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__noRel	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__noRel	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__Support	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	In eyes with synechial primary angle-closure or primary angle-closure glaucoma, both iridotomy alone or combined with iridoplasty provide a significant and equivalent reduction in IOP.
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	IOP was reduced from 24.66 +/- 13.76 mm Hg to 19.03 +/- 6.21 mm Hg in the iridotomy group (P < .001) and from 27.96 +/- 13.06 mm Hg to 20.45 +/- 7.26 mm Hg in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	Extent of peripheral anterior synechiae was decreased by 1 more clock-hour after iridoplasty compared with that after iridotomy in the iridotomy plus iridoplasty group (P < .001).
__label__noRel	There is also a possible reduction in peripheral anterior synechiae, more so in the iridoplasty group.	There was no significant difference in IOP, medications, need for surgery, or visual function between groups at the 1-year visit.
__label__noRel	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.
__label__Support	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.
__label__noRel	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).
__label__Support	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.
__label__noRel	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.	In an intent-to-treat analysis, the 2-year OS rates were 65.7% for CIS and 66.2% for TPZ/CIS (TPZ/CIS--CIS: 95% CI, -5.9% to 6.9%).
__label__noRel	We found no evidence that the addition of TPZ to chemoradiotherapy, in patients with advanced head and neck cancer not selected for the presence of hypoxia, improves OS.	There were no significant differences in failure-free survival, time to locoregional failure, or quality of life as measured by Functional Assessment of Cancer Therapy-Head and Neck.
__label__noRel	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.
__label__Support	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.
__label__noRel	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.
__label__Support	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.
__label__noRel	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.	The scapula-oriented exercise group showed improvements in pain, physical function, social function, and global quality of life compared with baseline, whereas the general exercise group showed improved fatigue and range of motion.
__label__noRel	Scapula-oriented exercise had beneficial effects on pain, quality of life and aspects of strength.	The change in global quality of life (P = 0.067; effect size, 0.33) and strength of external rotation (P = 0.001; effect size, 0.55) were significantly greater in the scapula-oriented exercise group than in the general exercise and control group.
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	recovery was found at both 6 months and 1 year in both groups.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__Support	recovery was found at both 6 months and 1 year in both groups.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	recovery was found at both 6 months and 1 year in both groups.
__label__Support	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	There were no significant differences between the narrow gastric tube group (NGT group, n=52) and the whole-stomach group (WS group, n=52) with regard to patient and cancer characteristics, operative procedure, postoperative intensive care unit (ICU) hospitalisation, and overall survival at 1 year.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	Regarding the postoperative complication, there were more cases of postoperative reflux oesophagitis and impairment of pulmonary function in the WS group (P<0.05).
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	Regarding the QoL investigation, the scores of QoL dropped for all patients at 3 weeks after surgery.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	recovery was found at both 6 months and 1 year in both groups.
__label__noRel	Patients who underwent gastric tube reconstruction develop less postoperative digestive tract complications, and have a quicker recovery and a better QoL during the follow-up period.	Patients in the NGT group reported significantly (P<0.05) better scores of QoL at both 6 months and 1 year.
__label__noRel	Male sexual dysfunction was significantly increased following surgery (P < .001),	although there was no difference between treatment arms.
__label__noRel	Male sexual dysfunction was significantly increased following surgery (P < .001),	Both treatment groups reported similar levels of decreased physical function at 3 months,
__label__noRel	Male sexual dysfunction was significantly increased following surgery (P < .001),	but thereafter it returned to baseline levels.
__label__noRel	Male sexual dysfunction was significantly increased following surgery (P < .001),	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,
__label__noRel	Male sexual dysfunction was significantly increased following surgery (P < .001),	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
__label__Support	Male sexual dysfunction was significantly increased following surgery (P < .001),	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,
__label__noRel	Male sexual dysfunction was significantly increased following surgery (P < .001),	PRE also affected sexual and some aspects of bowel functioning.
__label__Attack	although there was no difference between treatment arms.	Male sexual dysfunction was significantly increased following surgery (P < .001),
__label__noRel	although there was no difference between treatment arms.	Both treatment groups reported similar levels of decreased physical function at 3 months,
__label__noRel	although there was no difference between treatment arms.	but thereafter it returned to baseline levels.
__label__noRel	although there was no difference between treatment arms.	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,
__label__noRel	although there was no difference between treatment arms.	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
__label__noRel	although there was no difference between treatment arms.	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,
__label__noRel	although there was no difference between treatment arms.	PRE also affected sexual and some aspects of bowel functioning.
__label__noRel	Both treatment groups reported similar levels of decreased physical function at 3 months,	Male sexual dysfunction was significantly increased following surgery (P < .001),
__label__noRel	Both treatment groups reported similar levels of decreased physical function at 3 months,	although there was no difference between treatment arms.
__label__noRel	Both treatment groups reported similar levels of decreased physical function at 3 months,	but thereafter it returned to baseline levels.
__label__noRel	Both treatment groups reported similar levels of decreased physical function at 3 months,	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,
__label__noRel	Both treatment groups reported similar levels of decreased physical function at 3 months,	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
__label__Support	Both treatment groups reported similar levels of decreased physical function at 3 months,	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,
__label__noRel	Both treatment groups reported similar levels of decreased physical function at 3 months,	PRE also affected sexual and some aspects of bowel functioning.
__label__noRel	but thereafter it returned to baseline levels.	Male sexual dysfunction was significantly increased following surgery (P < .001),
__label__noRel	but thereafter it returned to baseline levels.	although there was no difference between treatment arms.
__label__Attack	but thereafter it returned to baseline levels.	Both treatment groups reported similar levels of decreased physical function at 3 months,
__label__noRel	but thereafter it returned to baseline levels.	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,
__label__noRel	but thereafter it returned to baseline levels.	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
__label__noRel	but thereafter it returned to baseline levels.	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,
__label__noRel	but thereafter it returned to baseline levels.	PRE also affected sexual and some aspects of bowel functioning.
__label__noRel	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,	Male sexual dysfunction was significantly increased following surgery (P < .001),
__label__noRel	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,	although there was no difference between treatment arms.
__label__noRel	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,	Both treatment groups reported similar levels of decreased physical function at 3 months,
__label__noRel	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,	but thereafter it returned to baseline levels.
__label__noRel	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
__label__noRel	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,
__label__Attack	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,	PRE also affected sexual and some aspects of bowel functioning.
__label__noRel	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.	Male sexual dysfunction was significantly increased following surgery (P < .001),
__label__noRel	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.	although there was no difference between treatment arms.
__label__noRel	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.	Both treatment groups reported similar levels of decreased physical function at 3 months,
__label__noRel	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.	but thereafter it returned to baseline levels.
__label__Attack	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,
__label__noRel	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,
__label__noRel	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.	PRE also affected sexual and some aspects of bowel functioning.
__label__noRel	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,	Male sexual dysfunction was significantly increased following surgery (P < .001),
__label__noRel	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,	although there was no difference between treatment arms.
__label__noRel	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,	Both treatment groups reported similar levels of decreased physical function at 3 months,
__label__noRel	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,	but thereafter it returned to baseline levels.
__label__noRel	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,
__label__noRel	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
__label__noRel	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,	PRE also affected sexual and some aspects of bowel functioning.
__label__noRel	PRE also affected sexual and some aspects of bowel functioning.	Male sexual dysfunction was significantly increased following surgery (P < .001),
__label__noRel	PRE also affected sexual and some aspects of bowel functioning.	although there was no difference between treatment arms.
__label__noRel	PRE also affected sexual and some aspects of bowel functioning.	Both treatment groups reported similar levels of decreased physical function at 3 months,
__label__noRel	PRE also affected sexual and some aspects of bowel functioning.	but thereafter it returned to baseline levels.
__label__noRel	PRE also affected sexual and some aspects of bowel functioning.	There was no evidence of any major changes between treatments or time points in terms of general health or bowel function,
__label__noRel	PRE also affected sexual and some aspects of bowel functioning.	but exploratory analysis indicated a significant (P = .006 at 2 years) increase in the level of fecal incontinence with PRE.
__label__noRel	PRE also affected sexual and some aspects of bowel functioning.	These results from a large randomized trial using validated patient-completed questionnaires show that, for males, the main adverse effect was sexual dysfunction, and the main cause of this was surgery,
__label__noRel	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.
__label__noRel	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).
__label__noRel	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.
__label__Support	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
__label__noRel	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).
__label__noRel	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).
__label__noRel	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.
__label__Support	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
__label__noRel	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).
__label__noRel	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.
__label__noRel	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.
__label__Support	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
__label__noRel	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).
__label__noRel	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.
__label__noRel	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).
__label__Support	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.
__label__noRel	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.	Using an area under the serum concentration-time curve analysis, there was no evidence that methylphenidate, as compared with placebo, improved the primary end point of cancer-related fatigue in this patient population (P = .35).
__label__noRel	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.	Comparisons of secondary end points, including clinically significant changes in quality-of-life variables and cancer-related fatigue change from baseline, were similarly negative.
__label__noRel	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.	However, a subset analysis suggested that patients with more severe fatigue and/or with more advanced disease did have some fatigue improvement with methylphenidate (eg, in patients with stage III or IV disease, the mean improvement in usual fatigue was 19.7 with methylphenidate v 2.1 with placebo; P = .02).
__label__noRel	This clinical trial was unable to support the primary prestudy hypothesis that the chosen long-acting methylphenidate product would decrease cancer-related fatigue.	There was a significant difference in self-reported toxicities (SED), with increased levels of nervousness and appetite loss in the methylphenidate arm.
__label__noRel	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
__label__noRel	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).
__label__noRel	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).
__label__Attack	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.
__label__Attack	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),
__label__noRel	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).
__label__noRel	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).
__label__noRel	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.
__label__noRel	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),
__label__noRel	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
__label__noRel	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).
__label__Support	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.
__label__noRel	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),
__label__noRel	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
__label__noRel	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).
__label__Support	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.
__label__noRel	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.	The total effective rate in the treatment group was: 84.38% (54/64), and in the control group it was 88.33% (53/60), showing no significant difference between them (P>0.05),
__label__noRel	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.	but the analgesia initiating time and the optimal analgesia effect revealing time in the treatment group were significantly shorter (both P<0.01).
__label__noRel	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.	XZP was better in improving patients' QOL, showing more significant improvements in the treatment group than those in the control group in aspects of mental condition, walking capacity, working capacity, social acceptability, sleep and joy of living (P<0.05 or P<0.01).
__label__noRel	Applying an external compress: of XZP showed a synergistic action with 3L analgesia for shortening the initiating time and the optimal effect revealing time, and could evidently enhance patients' QOL with fewer adverse reactions.	Lower incidence of adverse reactions, such as nausea, vomiting, mouth dryness, dizziness, etc., especially constipation, was noted in the treatment group (P<0.05 or P<0.01).
__label__noRel	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).
__label__noRel	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.
__label__Support	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.
__label__noRel	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.
__label__noRel	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.
__label__Support	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.
__label__noRel	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.
__label__noRel	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).
__label__Support	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.
__label__noRel	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.	At 1 year, IOP in both treatment groups was statistically significantly lower from baseline values.
__label__noRel	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.	Sixty-six percent of treatment eyes versus 48% of control eyes achieved =20% IOP reduction without medication (P = 0.003).
__label__noRel	Pressure reduction on fewer medications was clinically and statistically significantly better 1 year after stent plus cataract surgery versus cataract surgery alone, with an overall safety profile similar to that of cataract surgery alone.	The overall incidence of adverse events was similar between groups with no unanticipated adverse device effects.
__label__noRel	Systematic assessment is vital to palliative care	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	Systematic assessment is vital to palliative care	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__noRel	Systematic assessment is vital to palliative care	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	Systematic assessment is vital to palliative care	Systematic assessment of depression is needed in hospice patients.
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	Systematic assessment is vital to palliative care
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).	Systematic assessment of depression is needed in hospice patients.
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Systematic assessment is vital to palliative care
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.	Systematic assessment of depression is needed in hospice patients.
__label__noRel	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	Systematic assessment is vital to palliative care
__label__noRel	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__Support	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.	Systematic assessment of depression is needed in hospice patients.
__label__noRel	Systematic assessment of depression is needed in hospice patients.	Systematic assessment is vital to palliative care
__label__noRel	Systematic assessment of depression is needed in hospice patients.	Results showed improved patient depression (P < .001) as a result of the intervention and improvement in both groups in patients' quality of life (P < .001).
__label__noRel	Systematic assessment of depression is needed in hospice patients.	No other patient outcomes (symptom distress, spiritual needs) or caregiver outcomes (depression, support, spiritual needs) were significantly different.
__label__noRel	Systematic assessment of depression is needed in hospice patients.	Hospice care was so good during the study that overall quality of life improved as a result of standard care and left little room for improvement in other variables.
__label__noRel	With a median follow-up of 56·9 months (IQR 37·4-81·8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0·98, 95% CI 0·80-1·20, p=0·85).	Median survival from randomisation was 25·7 months (95% CI 23·0-27·9) for patients on early treatment and 27·1 months (22·8-30·9) for those on delayed treatment.
__label__Support	With a median follow-up of 56·9 months (IQR 37·4-81·8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0·98, 95% CI 0·80-1·20, p=0·85).	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,
__label__noRel	With a median follow-up of 56·9 months (IQR 37·4-81·8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0·98, 95% CI 0·80-1·20, p=0·85).	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
__label__noRel	Median survival from randomisation was 25·7 months (95% CI 23·0-27·9) for patients on early treatment and 27·1 months (22·8-30·9) for those on delayed treatment.	With a median follow-up of 56·9 months (IQR 37·4-81·8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0·98, 95% CI 0·80-1·20, p=0·85).
__label__Support	Median survival from randomisation was 25·7 months (95% CI 23·0-27·9) for patients on early treatment and 27·1 months (22·8-30·9) for those on delayed treatment.	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,
__label__noRel	Median survival from randomisation was 25·7 months (95% CI 23·0-27·9) for patients on early treatment and 27·1 months (22·8-30·9) for those on delayed treatment.	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
__label__noRel	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,	With a median follow-up of 56·9 months (IQR 37·4-81·8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0·98, 95% CI 0·80-1·20, p=0·85).
__label__noRel	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,	Median survival from randomisation was 25·7 months (95% CI 23·0-27·9) for patients on early treatment and 27·1 months (22·8-30·9) for those on delayed treatment.
__label__Support	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
__label__noRel	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	With a median follow-up of 56·9 months (IQR 37·4-81·8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0·98, 95% CI 0·80-1·20, p=0·85).
__label__noRel	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	Median survival from randomisation was 25·7 months (95% CI 23·0-27·9) for patients on early treatment and 27·1 months (22·8-30·9) for those on delayed treatment.
__label__noRel	and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone,
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__Support	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).
__label__Support	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	This study suggests that there was no benefit of Nd:YAG LPI in preventing progression from PDS with OHT to PG within 3 years of follow-up.
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	neodymium:yttrium-aluminum-garnet (Nd:YAG) laser peripheral iridotomy (LPI) significantly reduces the incidence of conversion from pigment dispersion syndrome (PDS) with ocular hypertension (OHT) to pigmentary glaucoma (PG).
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	Eight eyes (15%) in the laser group and 3 eyes (6%) in the control group converted to glaucoma in the study period.
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	The proportion of eyes started on medical treatment was similar in the 2 groups: 8 eyes (15%) in the laser group and 9 eyes (17%) in the control group.
__label__noRel	Cataract extraction was performed on 1 patient in the laser group and in 1 patient in the control group during the study period (laser eye at 18 months; control eye at 34 months).	Survival analyses showed no evidence of any difference in time to VF progression or commencement of topical therapy between the 2 groups.
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	One patient in each group required Baerveldt device implantation.
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__noRel	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__noRel	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	One patient in each group required Baerveldt device implantation.
__label__noRel	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__Support	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__noRel	One patient in each group required Baerveldt device implantation.	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	One patient in each group required Baerveldt device implantation.	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	One patient in each group required Baerveldt device implantation.	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__noRel	One patient in each group required Baerveldt device implantation.	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__Support	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	One patient in each group required Baerveldt device implantation.
__label__noRel	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	Scleral flap size had no significant effect on medium-term intraocular pressure control and complication profile.
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	At 2 years, the mean intraocular pressure and cumulative probability of failure was 12.4 ± 4.6 mmHg and 0.28 for standard trabeculectomy, and 11.5 ± 3.6 mmHg and 0.27 for microtrabeculectomy (P = 0.50 and 0.89, respectively).
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	One patient in each group required Baerveldt device implantation.
__label__noRel	Both trabeculectomy techniques achieved good intraocular pressure reduction and had similar complication rates.	Vision reduced ≥2 Snellen lines in 15% in the standard trabeculectomy group and 25% in the microtrabeculectomy group, mainly from cataract (P = 0.48).
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.	Both therapies were well tolerated.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__Support	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).	Both therapies were well tolerated.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__Support	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).	Both therapies were well tolerated.
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__Support	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.	Both therapies were well tolerated.
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__Support	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.	Both therapies were well tolerated.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__noRel	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.	Both therapies were well tolerated.
__label__noRel	Both therapies were well tolerated.	Both latanoprost and timolol had favorable safety profiles over the duration of this 3-month trial.
__label__noRel	Both therapies were well tolerated.	Mean IOP reductions for latanoprost and timolol at week 12 were 7.2 and 5.7 mmHg, respectively, with a difference of 1.5 mmHg (95% CI, -0.8 to 3.7; P=0.21).
__label__noRel	Both therapies were well tolerated.	Responder rates were 60% for latanoprost and 52% for timolol (P=0.33).
__label__noRel	Both therapies were well tolerated.	Between-treatment differences in mean IOP reduction for PCG and non-PCG subgroups were 0.6 mmHg (95% CI, -2.3 to 3.4) and 2.6 mmHg (95% CI, -0.8 to 6.1), respectively.
__label__noRel	Both therapies were well tolerated.	Responder rates for latanoprost versus timolol were 50% versus 46% for the PCG group and 72% versus 57% for the non-PCG group.
__label__noRel	Both therapies were well tolerated.	Latanoprost 0.005% is not inferior (i.e., is either more or similarly effective) to timolol and produces clinically relevant IOP reductions across pediatric patients with and without PCG.
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__noRel	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__Support	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__noRel	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__Support	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.
__label__Support	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
__label__noRel	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy.
__label__noRel	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	Mean IOP reduction across all visits and time points was 8.0 mm Hg in the TRA/TIM BAK-free group and 8.4 mm Hg in the TRA/TIM group (P=0.0943).
__label__noRel	The most common drug-related adverse event was hyperemia of the eye (ocular hyperemia and conjunctival hyperemia combined), occurring in 11.8% of the TRA/TIM BAK-free group and 13.0% of the TRA/TIM group.	The difference in mean IOP between groups ranged from 0.2 to 0.7  mm Hg across visits and time points, with a mean pooled difference of 0.4  mm Hg (95% CI: -0.1 to 0.8),
__label__noRel	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.
__label__noRel	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.	No significant difference in any of these measures was noted in the control group.
__label__Support	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.
__label__noRel	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.	No significant difference in any of these measures was noted in the control group.
__label__Support	No significant difference in any of these measures was noted in the control group.	This study demonstrates that a brief, predominantly group-based resilience training intervention is feasible in patients with previous breast cancer; also, it may be efficacious.
__label__noRel	No significant difference in any of these measures was noted in the control group.	A statistically significant improvement in resilience, perceived stress, anxiety, and overall quality of life at 12 weeks, compared with baseline was observed in the study arm.
__label__noRel	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__noRel	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__Support	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__Support	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__noRel	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__noRel	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__noRel	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	Analysing response to FUFA and FOLFIRI in the per protocol set (n=119) after un-blinding TS in the data base revealed a trend to better overall response to FOLFIRI (9/19, 47%) in TS high compared to FUFA (5/23, 22%, p=0.077).
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	In patients with biopsies taken from liver lesions (n=91) overall response to FOLFIRI and FUFA in TS high was 53% (9/17) and 18% (3/17), respectively (p=0.035).
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	In patients with low TS, no remarkable difference in overall response to FOLFIRI and FUFA was observed.
__label__noRel	After validation of our data in a larger group TS determination may have the potential to better help direct systemic treatment in patients with primarily non-resectable mCRC.	Taking a pre-treatment biopsy is a safe and feasible procedure in mCRC.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Toxicities were generally mild in both groups.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Toxicities were generally mild in both groups.
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Toxicities were generally mild in both groups.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Toxicities were generally mild in both groups.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Toxicities were generally mild in both groups.	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Toxicities were generally mild in both groups.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Toxicities were generally mild in both groups.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Toxicities were generally mild in both groups.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__Support	Toxicities were generally mild in both groups.	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Toxicities were generally mild in both groups.	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Toxicities were generally mild in both groups.
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__noRel	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__Support	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Toxicities were generally mild in both groups.
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__Support	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Toxicities were generally mild in both groups.
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__noRel	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Objective response rates were 22.8% (13 of 57) in E and 8.9% (5 of 56) in V (p = 0.0388).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Median progression-free survival (PFS) was 4.57 months in E and 2.53 months in V (p = 0.0287), with an 80.6% increase in median PFS for E compared with V.
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Median survival time was 11.67 months in E and 9.3 months in V (p = 0.6975).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Toxicities were generally mild in both groups.
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Median PFS was longest for epidermal growth factor receptor gene (EGFR)-mutated patients in the E group, followed by EGFR-mutated patients in V, EGFR wild type in E, and EGFR wild type in V (p = 0.0034).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Overall survival was longer for EGFR-mutated patients than for EGFR wild-type patients (p < 0.0001).
__label__noRel	EGFR-mutated patients had better survival than those with EGFR wild-type disease, regardless of the treatment received.	Erlotinib is highly effective compared with oral vinorelbine in elderly, chemonaive, Taiwanese patients with NSCLC.
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Risk for distress accounted for very few moderation effects.
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	but few sustained effects.
__label__Support	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Risk for distress accounted for very few moderation effects.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Risk for distress accounted for very few moderation effects.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Risk for distress accounted for very few moderation effects.	but few sustained effects.
__label__noRel	Risk for distress accounted for very few moderation effects.	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Risk for distress accounted for very few moderation effects.
__label__noRel	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	but few sustained effects.
__label__Support	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	but few sustained effects.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	but few sustained effects.	Risk for distress accounted for very few moderation effects.
__label__Attack	but few sustained effects.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	but few sustained effects.	Patient-caregiver dyads benefit when viewed as the 'unit of care'.
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Significant group by time interactions showed that there was an improvement in dyads' coping (p < 0.05), self-efficacy (p < 0.05), and social QOL (p < 0.01) and in caregivers' emotional QOL (p < 0.05).
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Risk for distress accounted for very few moderation effects.
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	Both brief and extensive programs had positive outcomes for patient-caregiver dyads,
__label__noRel	Patient-caregiver dyads benefit when viewed as the 'unit of care'.	but few sustained effects.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Support	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__Support	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__noRel	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	By cycle 4, mean differences were clinically meaningful for most domains, indicating poorer health status with VMP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	From cycle 5 onwards, improvements relative to baseline/MP were observed for all domains with VMP.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Mean scores were generally improved by the end-of-treatment assessment vs. baseline in both arms.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Among responding patients, mean scores generally improved from time of response to end-of-treatment assessment, substantially driven by patients achieving complete response (CR).
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Multivariate analysis showed a significant impact of duration of response/CR on improving global health status, pain, and appetite loss scores.
__label__noRel	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	Analyses by bortezomib dose intensity indicated better HRQoL in patients receiving lower dose intensity.
__label__Attack	However, HRQoL is not compromised in the long term, recovering by the end-of-treatment visit to be comparable vs. MP.	These findings demonstrate clinically meaningful, transitory HRQoL decrements with VMP and relatively lower HRQoL vs. MP during early treatment cycles, associated with the expected additional toxicities.
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Support	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Support	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).
__label__noRel	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).
__label__noRel	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Support	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__noRel	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	There were no statistically significant differences in FOIS scores between intervention and control patients immediately after CRT (immediately after CRT: intervention group median score, 3 [range, 1-7], vs median control score, 4 [range, 1-6] (P = .88).
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	intervention patients had significantly better scores at months 3 and 6 (median 3-month intervention score, 7 [range, 5-7], vs median control score, 5 [range, 3-7] [P = .03]; median 6-month intervention score, 7 [range, 6-7], vs median control score, 6 [range, 3-7] [P = .009]).
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	There was no significant difference in scores at months 9 and 12 (P = .24 and P = .93, respectively).
__label__noRel	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	The same pattern between intervention and control patients was observed for scores on the PSS-H&N.
__label__Attack	The small sample size may have limited our ability to detect significant differences beyond 6 months of observation as well as additional significant differences in our study.	Patients who performed prophylactic swallowing exercises had improved swallowing function at 3 and 6 months after CRT but not immediately after CRT or at 9 and 12 months after CRT.
__label__noRel	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect = -0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect = .11).
__label__noRel	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect = 0.60).
__label__noRel	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect = -0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect = .11).	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.
__label__noRel	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect = -0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect = .11).	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect = 0.60).
__label__Support	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect = 0.60).	Findings suggest that self-efficacy may influence long-term maintenance of healthy lifestyle practices among cancer survivors.
__label__noRel	Change in self-efficacy for fat restriction partially accounted for the intervention's impact on overall diet quality among men only (mean indirect effect = 0.60).	Results suggest that change in self-efficacy for fat restriction partially explained the intervention's effect on fat intake (mean indirect effect = -0.28), and change in self-efficacy for F&V consumption partially explained the intervention's effect on daily F&V intake (mean indirect effect = .11).
__label__noRel	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 0·30, 95% CI 0·12-0·76; p=0·005).	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (0·35, 0·16-0·78; p=0·005).
__label__noRel	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 0·30, 95% CI 0·12-0·76; p=0·005).	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.
__label__Support	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 0·30, 95% CI 0·12-0·76; p=0·005).	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.
__label__noRel	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (0·35, 0·16-0·78; p=0·005).	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 0·30, 95% CI 0·12-0·76; p=0·005).
__label__noRel	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (0·35, 0·16-0·78; p=0·005).	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.
__label__Support	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (0·35, 0·16-0·78; p=0·005).	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.
__label__noRel	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 0·30, 95% CI 0·12-0·76; p=0·005).
__label__noRel	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (0·35, 0·16-0·78; p=0·005).
__label__noRel	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.
__label__noRel	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.	16 (29%) patients in the open oesophagectomy group had pulmonary infection in the first 2 weeks compared with five (9%) in the minimally invasive group (relative risk [RR] 0·30, 95% CI 0·12-0·76; p=0·005).
__label__noRel	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.	19 (34%) patients in the open oesophagectomy group had pulmonary infection in-hospital compared with seven (12%) in the minimally invasive group (0·35, 0·16-0·78; p=0·005).
__label__noRel	These findings provide evidence for the short-term benefits of minimally invasive oesophagectomy for patients with resectable oesophageal cancer.	For in-hospital mortality, one patient in the open oesophagectomy group died from anastomotic leakage and two in the minimally invasive group from aspiration and mediastinitis after anastomotic leakage.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	The incidence and development of cancer are closely related to dysfunction of immune function.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__Support	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__Support	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__Support	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__Support	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	The incidence and development of cancer are closely related to dysfunction of immune function.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	DC/CIK treatment prolongs progression-free survival (3.20 months [95% CI, 2.94-3.50] vs 2.56 months [95% CI, 2.39-2.73]; P <0.05).
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	In the treatment group, the proportion of NK cells, T-cell subgroups CD3+, CD4+ and CD8+ had a significant change before and after treatment.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	Liver and kidney function and blood tests of the treatment group were within the normal range before and after treatment.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	In the treatment group, 1 case suffered from chest distress, 3 cases suffered from acratia, and 4 cases suffered from pyrexia.
__label__noRel	DC/CIK treatment is a safe and effective method for maintenance therapy of advanced non-small cell lung cancer.	DC/CIK treatment had potential benefit for patients with advanced non-small cell lung cancer compared with the control group and had no obvious side effects.
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__noRel	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__Support	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__Support	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__Support	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__noRel	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__Support	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__noRel	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.	However, it provided no improvement in PFS or OS compared with flat dosing.
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93].
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001).
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001).
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82).
__label__noRel	However, it provided no improvement in PFS or OS compared with flat dosing.	In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value.
__label__Attack	However, it provided no improvement in PFS or OS compared with flat dosing.	Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.
__label__Support	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).	Despite small numbers, the main effect size was robust.
__label__noRel	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).	We recommend implementation alongside evaluation in wider clinical settings and patient populations.
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.
__label__Support	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.	Despite small numbers, the main effect size was robust.
__label__noRel	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.	We recommend implementation alongside evaluation in wider clinical settings and patient populations.
__label__noRel	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).
__label__noRel	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.
__label__Support	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.	Despite small numbers, the main effect size was robust.
__label__noRel	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.	We recommend implementation alongside evaluation in wider clinical settings and patient populations.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	Despite small numbers, the main effect size was robust.
__label__noRel	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.	We recommend implementation alongside evaluation in wider clinical settings and patient populations.
__label__noRel	Despite small numbers, the main effect size was robust.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).
__label__noRel	Despite small numbers, the main effect size was robust.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.
__label__noRel	Despite small numbers, the main effect size was robust.	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.
__label__noRel	Despite small numbers, the main effect size was robust.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__Attack	Despite small numbers, the main effect size was robust.	We recommend implementation alongside evaluation in wider clinical settings and patient populations.
__label__noRel	We recommend implementation alongside evaluation in wider clinical settings and patient populations.	The primary outcome was significantly lower in the intervention arm (adjusted difference -16.8, 95% CI -28.34 to -5.3; P = 0.006).
__label__noRel	We recommend implementation alongside evaluation in wider clinical settings and patient populations.	The SCNS physical and patient care subscales (-14.2, 95% CI -26.2 to -2.2; P = 0.02 and -7.4, 95% CI -13.7 to -1.1; P = 0.02, respectively) and self-reported health state (12.8, 95% CI 3.2 to 22.4; P = 0.01) also differed significantly.
__label__noRel	We recommend implementation alongside evaluation in wider clinical settings and patient populations.	The incremental cost-effectiveness ratio was £19,390 per quality-adjusted life year.
__label__Attack	We recommend implementation alongside evaluation in wider clinical settings and patient populations.	This intervention significantly reduced the unmet needs of cancer survivors and it is likely that it is cost-effective.
__label__noRel	We recommend implementation alongside evaluation in wider clinical settings and patient populations.	Despite small numbers, the main effect size was robust.
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	the 2-year somatic functions and psychological functions decreased in the treatment group;	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	the 2-year somatic functions and psychological functions decreased in the treatment group;	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__Support	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__Support	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with the control group of the same period, the 6-month and 1-year WBC and Hb increased, the 1-year PLT increased in the treatment group, showing statistical difference (P<0.05, P<0.01).
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with 1-year treatment in the treatment group, the 2-and 3-year psychological functions and the general symptoms scores decreased (P<0.05, P<0.01).
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with the control group of the same period, the 2-and 3-year somatic functions, psychological functions, and the general symptoms scores decreased in the treatment group;
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	the 2-year somatic functions and psychological functions decreased in the treatment group;
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	the 3-year psychological functions and the general symptoms scores decreased in the treatment group, all with statistical difference (all P<0.05).
__label__noRel	FJD combined chemotherapy could effectively improve the QOL of solid tumor children patients, elevate their survival rate, and prolong their life spans.	Compared with the control group, the death number decreased, the survival rate increased, the life span of dead children was prolonged in the treatment group, showing statistical difference (P<0.05).
__label__noRel	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.
__label__noRel	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.
__label__Support	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
__label__noRel	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.
__label__Support	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.	LLLT was effective in improving the patient's subjective experience of OM and QOL in HNC patients receiving CRT.
__label__noRel	Results analysis revealed that OMWQ-HN (F = 12.199, df = 6,1314, p < 0.001) and FACT-HN (p < 0.05) scores were significantly lower in LLLT than placebo group patients.	a significant reduction (p < 0.001) in incidence of severe OM, need for opioid analgesics, and total parenteral nutrition was observed.
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	women with higher intrusions at baseline started worse and remained worse over time.
__label__Support	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	women with higher intrusions at baseline started worse and remained worse over time.
__label__Support	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	women with higher intrusions at baseline started worse and remained worse over time.
__label__Support	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	women with higher intrusions at baseline started worse and remained worse over time.
__label__Attack	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	women with higher intrusions at baseline started worse and remained worse over time.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__Support	women with higher intrusions at baseline started worse and remained worse over time.	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	Intrusive thoughts were associated with higher levels of all symptoms at baseline and at the 12-month assessment.
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	Intrusive thoughts also influenced the trajectory of pain, depressive symptoms, negative affect, and physical functioning over time;
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	women with higher intrusions at baseline started worse and improved over time, whereas those with lower intrusions remained at a constant, lower level over time.
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	Intrusions were not associated with the trajectory of fatigue, sleep, breast cancer-specific symptoms, or mental functioning;
__label__noRel	Intrusive thoughts are associated with enduring elevations in behavioral symptoms and impaired quality of life in the year after breast cancer treatment and may be a risk factor for poor outcomes.	women with higher intrusions at baseline started worse and remained worse over time.
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);	Incontinence did not correlate with EUS or IUS dose.
__label__Support	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);
__label__noRel	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);
__label__noRel	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).
__label__noRel	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);	Incontinence did not correlate with EUS or IUS dose.
__label__Support	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);
__label__noRel	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);
__label__noRel	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).
__label__noRel	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);	Incontinence did not correlate with EUS or IUS dose.
__label__Support	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);
__label__noRel	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);
__label__noRel	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);
__label__noRel	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).	Incontinence did not correlate with EUS or IUS dose.
__label__Support	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	Incontinence did not correlate with EUS or IUS dose.	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).
__label__noRel	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	Incontinence did not correlate with EUS or IUS dose.
__label__Support	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	Urinary function declined when the IUS V285 was 0.4% (ρ=-0.32, p=0.04);
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	bother worsened when the IUS V35 was 99% (ρ=-0.31, p=0.05) or the EUS V240 was 63% (ρ=-0.31, p=0.05);
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	irritation increased when the IUS V35 was 95% (ρ=-0.37, p=0.02) and the EUS V265 was 24% (ρ=-0.32, p=0.04);
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	urgency worsened when the IUS V35 was 99.5% (ρ=-0.38, p=0.02).
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	Incontinence did not correlate with EUS or IUS dose.
__label__noRel	Incorporating MRI-based dose-volume histogram analysis into the treatment planning process may reduce acute urinary morbidity after brachytherapy.	Doses to the IUS and EUS on MRI/CT predicted worse urinary function, with greater bother, irritative symptoms, and urgency.
__label__noRel	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__noRel	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__Support	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__Support	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__Support	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__noRel	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.
__label__noRel	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	Maintenance therapy with erlotinib did not impact on deterioration in HRQoL: TSP (hazard ratio [HR]=0.91 [95% confidence interval (CI) 0.74-1.12]; n=785), TTD in TOI (HR=1.06 [95% CI 0.87-1.31]; n=781) and TTD in HRQoL (HR=0.96 [95% CI 0.79-1.16]; n=776).
__label__noRel	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	Time to pain and time to analgesic use were significantly delayed in patients receiving erlotinib compared with placebo (HR=0.61 [95% CI 0.42-0.88]; p=0.0080 and HR=0.66 [95% CI 0.46-0.94]; p=0.0199, respectively).
__label__noRel	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	A non-significant trend towards delayed time to cough and time to dyspnoea (HR=0.77 [95% CI 0.49-1.21] and HR=0.75 [95% CI 0.48-1.17], respectively) was also observed.
__label__Support	Compared with placebo, erlotinib maintenance therapy prolonged progression-free and overall survival by 41% and 23%, respectively.	Erlotinib maintenance therapy significantly extends progression-free survival without compromising patient HRQoL in comparison with placebo, with some improvement in symptoms.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	Intraperitoneal administration limits cardiotoxicity of verapamil.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__Support	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__Support	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__Support	cumulative survival rate was also significantly higher in the combined treatment group.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	cumulative survival rate was also significantly higher in the combined treatment group.	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.
__label__Support	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	Intraperitoneal administration limits cardiotoxicity of verapamil.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	Intraperitoneal perfusion of verapamil enhances the efficacy of chemotherapy drugs, prolongs survival, and improves the quality of life.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	The combined treatment group demonstrated 13 cases of complete remission and 22 cases of partial remission.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	The treatment of control group led to 1 case of complete remission and 2 cases of partial remission, making the rate of efficacy (complete + partial remission) of 9.7 %.
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	the rate of efficacy was significantly higher in the combined treatment group (85.36 %; p < 0.05 vs. control group).
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	The quality of life improved in control group by 13.7 %, while combined treatment group showed improvement of 83.5 % (p < 0.05 vs. control group).
__label__noRel	Treatment toxicity and the rate of adverse effects and intestinal adhesion were not significantly different between study groups.	cumulative survival rate was also significantly higher in the combined treatment group.
__label__noRel	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__noRel	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	but decreased at end-of-treatment.
__label__noRel	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__noRel	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__noRel	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__Support	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	but decreased at end-of-treatment.
__label__noRel	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__Support	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__noRel	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__noRel	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__noRel	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	but decreased at end-of-treatment.
__label__noRel	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__noRel	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__Support	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__noRel	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	but decreased at end-of-treatment.	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	but decreased at end-of-treatment.	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__Attack	but decreased at end-of-treatment.	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	but decreased at end-of-treatment.	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	but decreased at end-of-treatment.	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__noRel	but decreased at end-of-treatment.	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__noRel	but decreased at end-of-treatment.	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__noRel	but decreased at end-of-treatment.	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__noRel	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	but decreased at end-of-treatment.
__label__noRel	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__noRel	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__Support	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__noRel	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__noRel	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	but decreased at end-of-treatment.
__label__noRel	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__noRel	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__Support	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__noRel	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	but decreased at end-of-treatment.
__label__noRel	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__Support	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__noRel	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	but decreased at end-of-treatment.
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__noRel	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.	overall survival, a secondary endpoint for the study, did not differ between the two groups,
__label__noRel	overall survival, a secondary endpoint for the study, did not differ between the two groups,	Median overall survival was 20.1 months (95% CI 16.7-23.4) with axitinib and 19.2 months (17.5-22.3) with sorafenib (hazard ratio [HR] 0.969, 95% CI 0.800-1.174; one-sided p=0.3744).
__label__noRel	overall survival, a secondary endpoint for the study, did not differ between the two groups,	Median investigator-assessed PFS was 8.3 months (95% CI 6.7-9.2) with axitinib and 5·7 months (4.7-6.5) with sorafenib (HR 0.656, 95% CI 0.552-0.779; one-sided p<0.0001).
__label__noRel	overall survival, a secondary endpoint for the study, did not differ between the two groups,	Patient-reported outcomes scores were similar in the treatment groups at baseline, were maintained during treatment,
__label__noRel	overall survival, a secondary endpoint for the study, did not differ between the two groups,	but decreased at end-of-treatment.
__label__noRel	overall survival, a secondary endpoint for the study, did not differ between the two groups,	Common grade 3 or higher treatment-related adverse events were hypertension (60 [17%]), diarrhoea (40 [11%]), and fatigue (37 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]), and diarrhoea (27 [8%]) in 355 sorafenib-treated patients.
__label__noRel	overall survival, a secondary endpoint for the study, did not differ between the two groups,	In a post-hoc 12-week landmark analysis, median overall survival was longer in patients with a diastolic blood pressure of 90 mm Hg or greater than in those with a diastolic blood pressure of less than 90 mm Hg: 20.7 months (95% CI 18.4-24.6) versus 12.9 months (10.1-20.4) in the axitinib group (p=0.0116), and 20.2 months (17.1-32.0) versus 14.8 months (12.0-17.7) in the sorafenib group (one-sided p=0.0020).
__label__noRel	overall survival, a secondary endpoint for the study, did not differ between the two groups,	investigator-assessed PFS remained longer in the axitinib group compared with the sorafenib group.
__label__Attack	overall survival, a secondary endpoint for the study, did not differ between the two groups,	These results establish axitinib as a second-line treatment option for patients with metastatic renal cell carcinoma.
__label__noRel	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).
__label__noRel	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;	No statistically significant differences were found for secondary outcomes.
__label__noRel	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.
__label__Support	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,
__label__noRel	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
__label__noRel	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
__label__Attack	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;
__label__noRel	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).	No statistically significant differences were found for secondary outcomes.
__label__noRel	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.
__label__noRel	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,
__label__noRel	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
__label__noRel	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
__label__noRel	No statistically significant differences were found for secondary outcomes.	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;
__label__noRel	No statistically significant differences were found for secondary outcomes.	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).
__label__noRel	No statistically significant differences were found for secondary outcomes.	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.
__label__noRel	No statistically significant differences were found for secondary outcomes.	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,
__label__noRel	No statistically significant differences were found for secondary outcomes.	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
__label__noRel	No statistically significant differences were found for secondary outcomes.	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
__label__noRel	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;
__label__noRel	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).
__label__noRel	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.	No statistically significant differences were found for secondary outcomes.
__label__Support	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,
__label__noRel	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
__label__noRel	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
__label__noRel	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;
__label__noRel	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).
__label__noRel	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,	No statistically significant differences were found for secondary outcomes.
__label__noRel	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.
__label__noRel	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
__label__noRel	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
__label__noRel	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;
__label__noRel	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).
__label__noRel	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.	No statistically significant differences were found for secondary outcomes.
__label__noRel	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.
__label__Attack	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,
__label__noRel	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.
__label__noRel	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.	Participants in the intervention group reported, on average, 53 fewer days of sick leave over the first 6 months post-surgery than those in the control group;
__label__noRel	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.	however, this difference was not statistically significant (p = 0.122; 95% confidence interval -15.8, 122.0).
__label__noRel	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.	No statistically significant differences were found for secondary outcomes.
__label__noRel	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.	Interviews with trial participants indicated that trial procedures, including recruitment, randomisation and research instruments, were acceptable.
__label__noRel	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.	Conducting a pragmatic trial of effectiveness of a VR intervention among cancer survivors is both feasible and acceptable,
__label__noRel	VR to assist breast cancer patients in the return to work process is an important component of cancer survivorship plans.	but more research about the exact components of a VR intervention and choice of outcomes to measure effectiveness is required.
__label__noRel	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).
__label__noRel	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).
__label__noRel	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
__label__Support	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.
__label__noRel	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.
__label__noRel	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).	These findings have important implications for the treatment of patients with head and neck cancer.
__label__noRel	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).
__label__noRel	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).
__label__noRel	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
__label__noRel	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.
__label__noRel	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.
__label__noRel	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).	These findings have important implications for the treatment of patients with head and neck cancer.
__label__noRel	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).
__label__noRel	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).
__label__noRel	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
__label__Support	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.
__label__noRel	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.
__label__noRel	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).	These findings have important implications for the treatment of patients with head and neck cancer.
__label__noRel	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).
__label__noRel	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).
__label__noRel	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).
__label__noRel	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.
__label__Support	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.
__label__noRel	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.	These findings have important implications for the treatment of patients with head and neck cancer.
__label__noRel	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).
__label__noRel	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).
__label__noRel	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).
__label__noRel	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
__label__noRel	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.
__label__Support	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.	These findings have important implications for the treatment of patients with head and neck cancer.
__label__noRel	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).
__label__noRel	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).
__label__noRel	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).
__label__noRel	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
__label__noRel	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.
__label__Support	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.	These findings have important implications for the treatment of patients with head and neck cancer.
__label__noRel	These findings have important implications for the treatment of patients with head and neck cancer.	Significantly fewer patients receiving escitalopram developed depression (24.6% in the placebo group vs 10.0% in the escitalopram group; stratified log-rank test, P = .04).
__label__noRel	These findings have important implications for the treatment of patients with head and neck cancer.	The hazard ratio of 0.37 (95% CI, 0.14-0.96) demonstrated an advantage of escitalopram (P = .04).
__label__noRel	These findings have important implications for the treatment of patients with head and neck cancer.	Patients undergoing radiotherapy as the initial modality were significantly more likely to develop depression than those undergoing surgery (radiotherapy compared with surgery group; hazard ratio, 3.6; 95% CI, 1.38-9.40; P = .009).
__label__noRel	These findings have important implications for the treatment of patients with head and neck cancer.	Patients in the escitalopram group who completed the study and were not depressed rated their overall quality of life as significantly better for 3 consecutive months after cessation of drug use.
__label__noRel	These findings have important implications for the treatment of patients with head and neck cancer.	In nondepressed patients undergoing treatment for head and neck cancer, prophylactic escitalopram reduced the risk of developing depression by more than 50%.
__label__noRel	These findings have important implications for the treatment of patients with head and neck cancer.	In nondepressed patients who completed the trial, quality of life was also significantly better for 3 consecutive months after cessation of drug use in the escitalopram group.
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).
__label__noRel	However, the intervention was not found to reduce the risk of cancer recurrence and death.	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	Patients randomly assigned to the intervention arm showed significant improvements on symptoms of depression (p < 0.05) and anxiety (p < 0.05), health-related QOL (p < 0.05) (i.e. better global health status, and physical and emotional functioning, and less insomnia) when compared with controls.
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	In the subset analysis, female patients, those that received high dose irradiation, and those that underwent adjuvant chemotherapy could benefit more from psychosocial intervention.
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	There was no difference between the two groups in disease-free survival (DFS) (2-year DFS 79.8% in the intervention arm and 76.4% in the control arm; p = 0.527) and overall survival (OS) (2-year OS 83.1% in the intervention arm and 84.3% in the control arm; p = 0.925).
__label__noRel	Psychosocial intervention is a cost-effective approach that can improve a patient's mood and QOL both during and after RT.	However, the intervention was not found to reduce the risk of cancer recurrence and death.
__label__noRel	No effects of the intervention were found for any outcome after one year.	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,
__label__noRel	No effects of the intervention were found for any outcome after one year.	except for the bodily pain domain, four months after lung cancer surgery.
__label__noRel	No effects of the intervention were found for any outcome after one year.	We found no effect of the intervention on 6MWT or lung volumes at any time-point.
__label__noRel	No effects of the intervention were found for any outcome after one year.	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.
__label__noRel	No effects of the intervention were found for any outcome after one year.	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).
__label__Support	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,	No effects of the intervention were found for any outcome after one year.
__label__noRel	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,	except for the bodily pain domain, four months after lung cancer surgery.
__label__noRel	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,	We found no effect of the intervention on 6MWT or lung volumes at any time-point.
__label__noRel	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.
__label__noRel	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).
__label__noRel	except for the bodily pain domain, four months after lung cancer surgery.	No effects of the intervention were found for any outcome after one year.
__label__Attack	except for the bodily pain domain, four months after lung cancer surgery.	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,
__label__noRel	except for the bodily pain domain, four months after lung cancer surgery.	We found no effect of the intervention on 6MWT or lung volumes at any time-point.
__label__noRel	except for the bodily pain domain, four months after lung cancer surgery.	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.
__label__noRel	except for the bodily pain domain, four months after lung cancer surgery.	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).
__label__Support	We found no effect of the intervention on 6MWT or lung volumes at any time-point.	No effects of the intervention were found for any outcome after one year.
__label__noRel	We found no effect of the intervention on 6MWT or lung volumes at any time-point.	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,
__label__noRel	We found no effect of the intervention on 6MWT or lung volumes at any time-point.	except for the bodily pain domain, four months after lung cancer surgery.
__label__noRel	We found no effect of the intervention on 6MWT or lung volumes at any time-point.	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.
__label__noRel	We found no effect of the intervention on 6MWT or lung volumes at any time-point.	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).
__label__noRel	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.	No effects of the intervention were found for any outcome after one year.
__label__noRel	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,
__label__noRel	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.	except for the bodily pain domain, four months after lung cancer surgery.
__label__noRel	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.	We found no effect of the intervention on 6MWT or lung volumes at any time-point.
__label__Attack	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).
__label__Attack	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).	No effects of the intervention were found for any outcome after one year.
__label__noRel	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).	Supervised compared to unsupervised exercise training resulted in no improvement in health-related quality of life,
__label__noRel	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).	except for the bodily pain domain, four months after lung cancer surgery.
__label__noRel	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).	We found no effect of the intervention on 6MWT or lung volumes at any time-point.
__label__noRel	We found a statistically significant effect after four months in the bodily pain domain of SF36, with an estimated mean difference (EMD) of 15.3 (95% CI:4 to 26.6, p=0.01) and a trend in favour of the intervention for role physical functioning (EMD 12.04, 95% CI: -1 to 25.1, p=0.07) and physical component summary (EMD 3.76, 95% CI:-0.1 to 7.6, p=0.06).	At 12 months, the tendency was reversed, with the CG presenting overall slightly better measures.
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__noRel	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__noRel	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__Support	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__Support	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__Support	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy.
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	Rates of HBsAg loss at Week 72 were significantly higher in the TDF/PI-48w group (6.5%) than in the TDF/PI-16w+TDF-32w (0.5%), TDF-120w (0%) and PI-48w (2.2%) groups (P = 0.09).
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	HBsAg decline at Week 12 or 24 of treatment was associated with HBsAg loss at Week 72 (P < 0.001).
__label__noRel	HBsAg decline at Week 24 of TDF plus PEG-IFN combination therapy may identify patients who, after completing 48 weeks of treatment, have a better chance of achieving HBsAg loss at Week 72.	HBsAg decline >3.5 log10 IU/mL at Week 24 in the TDF/PI-48w group resulted in a positive predictive value of 85% and a negative predictive value of 99% for HBsAg loss at Week 72.
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	the SLT's effect was significant only during the nighttime.
__label__Support	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	the SLT's effect was significant only during the nighttime.
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__Support	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	the SLT's effect was significant only during the nighttime.
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__Support	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	the SLT's effect was significant only during the nighttime.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	the SLT's effect was significant only during the nighttime.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	the SLT's effect was significant only during the nighttime.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	the SLT's effect was significant only during the nighttime.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	the SLT's effect was significant only during the nighttime.	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	the SLT's effect was significant only during the nighttime.	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	the SLT's effect was significant only during the nighttime.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	the SLT's effect was significant only during the nighttime.
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.	travoprost better controls IOP fluctuations than SLT, especially during the daytime.
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	eyes in the SLT and the travoprost groups achieved a significant reduction in IOP compared with the baseline IOP values (-3.7 mm Hg [P = 0.002] vs -4.1 mm Hg [P < 0.001], respectively).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Ninety-six percent of NTG eyes in the travoprost group, and 82% of eyes in the SLT group had IOP fluctuations <3 mm Hg (P = 0.01).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Success in fluctuation reduction was 75% and 92% for the SLT and travoprost groups, respectively (P = 0.005).
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	the SLT's effect was significant only during the nighttime.
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	The effect of travoprost on IOP reduction in POAG and NTG patients was significant both during the daytime and the nighttime,
__label__noRel	travoprost better controls IOP fluctuations than SLT, especially during the daytime.	Both travoprost and SLT can significantly reduce the IOP in patients with POAG and NTG.
__label__noRel	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__noRel	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__Support	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__Support	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__Support	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	The mean survival time was significantly longer for the microcatheter group (p = 0.01).	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__noRel	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.	The need for reoperation for glaucoma was significantly lower in the microcatheter group.
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	At the end of the 2-year follow-up period, the complete success and the failure rates were 67% and 15%, respectively, in the microcatheter-assisted group versus 47% and 50% in the rigid probe trabeculotomy group (p = 0.006).
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	There was a tendency towards lower IOP in the microcatheter group at 1, 3, 6, 12 and 24 months postoperatively, with the difference in IOP reaching statistical significance at 6 months (p = 0.004).
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	The mean survival time was significantly longer for the microcatheter group (p = 0.01).
__label__noRel	The need for reoperation for glaucoma was significantly lower in the microcatheter group.	At 2 years postoperatively, microcatheter-assisted trabeculotomy still yielded superior results in terms of IOP control and success rates in children with primary congenital glaucoma.
__label__noRel	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__noRel	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__Support	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__noRel	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__Support	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__Support	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__Support	No major adverse events occurred and biochemical markers were similarly safe with both treatments.	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	Compared with metformin, COC plus spironolactone caused larger decreases in hirsutism score (mean difference 4.6 points, 95% CI: 2.6-6.7), total testosterone (1.1 nmol/L, 0.4-1.7), free testosterone (25 pmol/L, 12-39), androstenedione (5.5 nmol/L, 1.8-9.2) and dehydroepiandrosterone sulfate (2.7 μmol/L, 1.4-4.0).
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	Menstrual dysfunction was less frequent with COC plus spironolactone (OR: 0.06, 95% CI: 0.02-0.23).
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	No differences were found in frequencies of abnormal glucose tolerance (OR: 1.7, 95% CI: 0.7-4.4), dyslipidemia (OR: 0.6, 95% CI: 0.2-1.8) or hypertension (OR: 0.3, 95% CI: 0.5-2.0).
__label__noRel	COC plus spironolactone was more effective than metformin for symptoms of PCOS showing similar safety and overall neutral effects on cardiometabolic risk factors.	No major adverse events occurred and biochemical markers were similarly safe with both treatments.
__label__noRel	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).
__label__noRel	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).
__label__noRel	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.
__label__Support	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.
__label__noRel	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).
__label__noRel	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.
__label__noRel	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.
__label__noRel	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).
__label__noRel	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.
__label__noRel	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.	The results of our study suggest that patients previously infected with HBV and naturally immune to HBV were at greater odds of being diagnosed with ENKTL.
__label__noRel	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.	The results of the multivariable analysis showed that after adjustment for a set of known risk factors, patients previously infected with HBV (HBsAg-seronegative/anti-HBc-seropositive) and naturally immune to HBV (anti-HBs-seropositive/anti-HBc-seropositive) were at significantly greater odds of being diagnosed with ENKTL (AOR, 1.497; 95% CI 1.098-2.042, P=0.033 and AOR, 1.871; 95% CI 1.302-2.689, P=0.001, respectively).
__label__noRel	The odds of ENKTL diagnosis were not significantly associated with ABO blood type, cigarette smoking status or family history of cancer.	After adjusting for other factors, significantly greater odds of being diagnosed with ENKTL were observed among cases who reported ever drinking alcohol (AOR, 1.675; 95% CI 1.054-2.660, P=0.029).
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__Support	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)
__label__Support	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	In conclusion, co-infected patients with elevated HBV-replication at ART-initiation are more susceptible to HIV-related morbidity, especially invasive bacterial diseases, during treatment interruption.
__label__noRel	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	No increase in the incidence of non-HIV-related morbidity was observed for co-infected patients (P = 0.5), even at HBV-replication levels > 10,000 copies/mL (P = 0.7).
__label__noRel	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	The relative effect of CD4GT or 2/4-ART versus C-ART was not different between infection groups (P for interaction = 0.4).
__label__noRel	After a median 2.0 year (range = 0.2-3.1) follow-up, ≥ 1 serious HIV-related events occurred in 101 HIV mono-infected and 15 HIV-HBV co-infected patients (IR = 10.0 versus 13.2/100 person/years, respectively, P = 0.3)	Incidence of bacterial infections was also highest in the co-infected group with HBV-replication > 10,000 copies/mL (IR = 12.9 versus 3.3/100 person/years in HIV mono-infected patients, P = 0.001).
__label__noRel	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.
__label__noRel	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).
__label__noRel	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.
__label__noRel	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension
__label__noRel	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).
__label__Support	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.
__label__noRel	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension
__label__noRel	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.
__label__Support	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.
__label__Attack	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.	valsartan/cilnidipine combination would suppress the home morning blood pressure (BP) surge (HMBPS) more effectively than a valsartan/hydrochlorothiazide combination in patients with morning hypertension
__label__noRel	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.	At the end of the treatment period, the changes in nocturnal SBP and morning SBP from baseline were significant in both the valsartan/cilnidipine and valsartan/hydrochlorothiazide groups (P < .001): -5.0 vs -10.0 mm Hg (P = .035) and -10.7 vs -13.6 mm Hg (P = .142), respectively.
__label__noRel	Valsartan/cilnidipine could not significantly suppress HMBPS compared with valsartan/hydrochlorothiazide.	HMBPS was significantly decreased from baseline in both groups (P < .001), but there was no significant difference between the two groups: 14.4 mm Hg vs 14.0 mm Hg, respectively (P = .892).
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	No serious adverse reactions were observed.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__Support	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	No serious adverse reactions were observed.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__Support	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	None of the subjects in either group experienced viral reactivation based on per protocol analysis.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	No serious adverse reactions were observed.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	No serious adverse reactions were observed.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	No serious adverse reactions were observed.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__Support	No serious adverse reactions were observed.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	No serious adverse reactions were observed.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	No serious adverse reactions were observed.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	No serious adverse reactions were observed.
__label__Support	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	No serious adverse reactions were observed.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	No serious adverse reactions were observed.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	After a mean follow-up period of 96 weeks, the proportion of HBV reactivation observed was 6.8% (4/58) in the LAM+ADV group and 4.5% (5/111) in the TDF group by using intention-to-treat analysis (difference, -2.3%; 95% CI, -9.84-5.24%).
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	None of the subjects in either group experienced viral reactivation based on per protocol analysis.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	No serious adverse reactions were observed.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	In the subgroup analysis for estimated glomerular filtration rate (eGFR) before and after treatment, decreased eGFR was observed only in the TDF group with cirrhosis (85.22 vs. 79.83 mL/min/1.73 m2, p = 0.000).
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	Stable switching to TDF monotherapy yielded non-inferior results at 96 weeks compared to the results obtained with LAM+ADV combination therapy in patients with LAM-resistant CHB and undetectable HBV DNA.
__label__noRel	The efficacy of switching to tenofovir disoproxil fumarate (TDF) monotherapy from lamivudine (LAM) plus adefovir dipivoxil (ADV) combination therapy (stable switching) in patients with LAM-resistant chronic hepatitis B (CHB) and undetectable hepatitis B virus (HBV) DNA is not clear.	However, TDF monotherapy in patients with cirrhosis requires close attention with respect to renal function.
__label__noRel	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).
__label__noRel	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
__label__noRel	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
__label__noRel	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.
__label__noRel	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
__label__Support	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
__label__noRel	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.
__label__noRel	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).
__label__Support	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.
__label__noRel	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.	Spironolactone could be used as the fourth-line therapy in patients with resistant hypertension.
__label__noRel	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.	Systolic BP was reduced from 143.5 ± 8.2 mmHg to 137.10 ± 7.57 mmHg in the intervention group, while it did not change significantly in control (between group treatment difference = -4.5 mmHg, p = 0.004).
__label__noRel	Short course monotherapy with low dose spironolactone is effective in reducing systolic BP in patients with stage I essential hypertension.	There was no significant reduction of diastolic BP in the intervention group in comparison to placebo group (between group treatment difference = -1.3 mmHg, p = 0.099).
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	GS-9620 might therefore be included in therapies to increase the immune response to HBV.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__Support	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__Support	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__Support	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.
__label__Support	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	GS-9620 might therefore be included in therapies to increase the immune response to HBV.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	T cells collected at baseline before addition of GS-9620, when patients were receiving only nucleos(t)ide therapy, had greater responses to HBV than T cells from treatment-naïve patients, based on cytokine production in response to HBV peptides.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	However, during or after administration of GS-9620, T cells produced higher levels of cytokines compared to baseline.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	NK-cell activation and function increased after patients were given GS-9620, but the ability of NK cells to suppress T-cell responses was lower during GS-9620 therapy than before.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	Changes in T-cell or NK-cell function did not correlate with levels of hepatitis B surface antigen.
__label__noRel	Twelve weeks administration of GS-9620 had no significant effect on serum hepatitis B surface antigen levels, but did appear to increase T-cell and NK-cell responses and reduce the ability of NK to suppress T cells.	Serum levels of hepatitis B surface antigen did not decrease significantly compared to baseline in patients given any dose of GS-9620.
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__Support	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.	Aldosterone blood levels did not change.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__Support	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.	Aldosterone blood levels did not change.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Diastolic blood pressure did not change during the sessions.	Aldosterone blood levels did not change.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Diastolic blood pressure did not change during the sessions.
__label__Support	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.	Aldosterone blood levels did not change.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__noRel	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.	Aldosterone blood levels did not change.
__label__noRel	Aldosterone blood levels did not change.	Symptomatic hypotension did not develop in any of the patients during the wet session, compared to 4 (40%) during the dry session.
__label__noRel	Aldosterone blood levels did not change.	Systolic blood pressure adjusted to ultrafiltration was stable during the wet session, 0.22 mmHg/15 min (95% CI -0.27 to 0.70), P = 0.38, and significantly decreased during the dry session, -0.68 mmHg/15 min (95%CI -1.24 to -0.11), P = 0.02.
__label__noRel	Aldosterone blood levels did not change.	Diastolic blood pressure did not change during the sessions.
__label__noRel	Aldosterone blood levels did not change.	Mean atrial natriuretic peptide significantly increased in the wet session, by 31.36 pgr/mL (95%CI 8.73-53.99), P = 0.007, and slightly and insignificantly decreased in the dry session, by 21.66 pgr/mL (95% CI -52.59 to 9.25), P = 0.167.
__label__noRel	Aldosterone blood levels did not change.	Reduced effective circulating volume is a major cause for IDH, which can be prevented using head-out water immersion facilitated redistribution.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__Support	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__Support	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__Support	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__noRel	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	The cumulative probability of failure during the first year of follow-up was 17.3% in the tube group and 7.9% in the trabeculectomy group (P = 0.01; hazard ratio, 2.59; 95% confidence interval, 1.20-5.60).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Postoperative complications developed in 36 patients (29%) in the tube group and 48 patients (41%) in the trabeculectomy group (P = 0.06).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Serious complications requiring reoperation or producing a loss of 2 Snellen lines or more occurred in 1 patient (1%) in the tube group and 8 patients (7%) in the trabeculectomy group (P = 0.03).
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Trabeculectomy with MMC had a higher surgical success rate than tube shunt implantation after 1 year in the PTVT Study.
__label__noRel	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	The frequency of serious complications producing vision loss or requiring reoperation was lower after tube shunt surgery relative to trabeculectomy with MMC.
__label__Support	Mean ± standard deviation IOP was 13.8±4.1 mmHg in the tube group and 12.4±4.4 mmHg in the trabeculectomy group at 1 year (P = 0.01), and the number of glaucoma medications was 2.1±1.4 in the tube group and 0.9±1.4 in the trabeculectomy group (P < 0.001).	Lower IOP with use of fewer glaucoma medications was achieved after trabeculectomy with MMC compared with tube shunt surgery during the first year of follow-up.
__label__noRel	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.
__label__noRel	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).
__label__noRel	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.
__label__Support	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.
__label__noRel	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).
__label__noRel	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.
__label__noRel	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.
__label__Support	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.
__label__noRel	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.
__label__noRel	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.	Larger studies using physiologically standardized ginseng preparations are warranted to substantiate the present findings and to demonstrate therapeutic effectiveness of AG.
__label__Support	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.	AG extract added to conventional treatment provided an effective and safe adjunct in the management of T2DM.
__label__noRel	AG lowered systolic blood pressure (- 5.6 ± 2.7 mmHg; p < 0.001), increased NOx (+ 1.85 ± 2.13 µmol/L; p < 0.03), and produced a mean percent end-difference of - 12.3 ± 3.9% in LDL-C and - 13.9 ± 5.8% in LDL-C/HDL.	Compared to placebo, AG significantly reduced HbA1c (- 0.29%; p = 0.041) and fasting blood glucose (- 0.71 mmol/L; p = 0.008).
__label__noRel	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.
__label__noRel	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.
__label__noRel	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.
__label__noRel	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.
__label__noRel	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.
__label__noRel	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.
__label__noRel	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.
__label__noRel	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.
__label__noRel	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.
__label__noRel	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.	Ca consumption during the study was equivalent to 1200 mg/d during MD and 525 mg/d during CD.
__label__noRel	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.	There was a greater reduction in WC, SBP, DBP and LAP index after MD compared with CD.
__label__noRel	The consumption of approximately 1200 mg of Ca/d (700 mg from fat-free milk+500mg from other dietary sources) associated with an energy-restricted diet decreased some of the MetS components and cardiometabolic measures in adults with T2DM.	HDL:LDL ratio increased and total cholesterol, LDL-cholesterol, SBP, DBP and LAP index decreased only in MD.
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	but evidence from trials is inconclusive.
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	Observational data support a role for vitamin D in type 2 diabetes,	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__Attack	but evidence from trials is inconclusive.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	but evidence from trials is inconclusive.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	but evidence from trials is inconclusive.	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	but evidence from trials is inconclusive.	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	but evidence from trials is inconclusive.	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	but evidence from trials is inconclusive.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	but evidence from trials is inconclusive.
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__Support	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	but evidence from trials is inconclusive.
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	Observational data support a role for vitamin D in type 2 diabetes,
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	but evidence from trials is inconclusive.
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	At week 24, mean 25(OH)D changed by 20.5 and -1.6 ng/mL in the vitamin D and placebo groups, respectively (P < 0.001).
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	The vitamin D and placebo groups did not differ in change in ISR or HbA1c.
__label__noRel	Vitamin D3 at 4000 IU/d did not change ISR or HbA1c in patients with well-controlled type 2 diabetes on metformin not selected for vitamin D deficiency.	Among patients treated with lifestyle only (n = 28), vitamin D supplementation reduced HbA1c compared with placebo (-0.1% vs 0.3%, respectively; P = 0.034) at week 24.
__label__noRel	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.
__label__noRel	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.
__label__noRel	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).
__label__noRel	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.
__label__Support	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.
__label__noRel	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).
__label__noRel	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.
__label__noRel	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.
__label__noRel	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).
__label__noRel	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).	Risk of all three outcomes was higher for participants with chronic kidney disease or frailty.
__label__noRel	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).	Older age was also associated with greater risk of syncope, hypotension, and falls, but there was no age-by-treatment interaction for any of the SAE outcomes.
__label__Support	Randomization to intensive SBP control was associated with greater risk of an SAE involving hypotension (hazard ratio (HR) = 1.67, 95% confidence interval (CI) = 1.21-2.32, P = .002), and possibly syncope (HR = 1.32, 95% CI = 0.98-1.79, P = .07), but not falls (HR = 0.98, 95% CI = 0.75-1.29, P = .90).	Participants randomized to intensive SBP control had greater risk of hypotension and possibly syncope, but not falls.
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__noRel	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__Support	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__noRel	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__Support	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus (DM) type II, with conflicting results.
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Cinnamon supplementation led to improvement of all anthropometric (BMI, body fat, and visceral fat), glycemic (FPG, 2hpp, HbA1C, Fasting Insulin, and Insulin Resistance), and lipids (Cholesterol Total, LDL-c and HDL-c) outcomes (except for triglycerides level).
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	All observed changes (except for Cholesterol Total and LDL-c) were significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).
__label__noRel	These benefits are significantly more prominent in patients with higher baseline BMI (BMI ≥ 27).	Based on the study findings, cinnamon may improve anthropometric parameters, glycemic indices and lipid profile of patients with type II diabetes.
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__Support	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__Support	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).
__label__noRel	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	KAMUT khorasan is an ancient grain with widely acclaimed health benefits.
__label__Support	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	This study suggests that a short-term replacement diet with ancient KAMUT khorasan products is most effective in reducing metabolic risk factors and ameliorating the liver profile in patients with NAFLD.
__label__noRel	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	significant improvements in the liver steatosis grading, Doppler perfusion index values, and reactive oxygen species (ROS) production were evident after consumption of both the khorasan and control products.
__label__noRel	After the implementation of a general linear model for repeated measurements adjusted for baseline demographic details, risk factors, and medication, alanine aminotransferase (ALT) was significantly reduced by 12%, aspartate aminotransferase (AST) by 14%, alkaline phosphatase (ALP) by 8%, and cholesterol by 6% only in the khorasan group (p < 0.05 for all).	significant reductions in circulating proinflammatory tumor necrosis factor-alpha by 50%, interleukin l-receptor antagonist-alpha by 37%, interleukin-8 by 24%, and interferon gamma by 24% were evident only in participants who consumed the khorasan products (p < 0.05 for all).
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	but have not shown beneficial effects on eGFR.
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__Support	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__Attack	but have not shown beneficial effects on eGFR.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	but have not shown beneficial effects on eGFR.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	but have not shown beneficial effects on eGFR.	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__noRel	but have not shown beneficial effects on eGFR.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	but have not shown beneficial effects on eGFR.	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	but have not shown beneficial effects on eGFR.	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	but have not shown beneficial effects on eGFR.
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__Support	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	but have not shown beneficial effects on eGFR.
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__Attack	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	but have not shown beneficial effects on eGFR.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	There may be salutary effects of incretin-based treatments on the diabetic kidney,	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	but have not shown beneficial effects on eGFR.
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__Attack	but the system is complex and not amenable to simple explanation or prior prediction.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__noRel	but the system is complex and not amenable to simple explanation or prior prediction.	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	Large-scale clinical trials have shown that incretin-based therapies mitigate albuminuria
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	but have not shown beneficial effects on eGFR.
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	Research on the incretin-based therapies has yielded a diverse array of direct effects throughout the body, which fuels speculation as to how these drugs might benefit the diabetic kidney and affect its function(s).
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	But in vivo experiments have yet to confirm that the proposed mechanisms underlying emergent phenomena, such as proximal tubular fluid reabsorption, are the ones predicted by cell and molecular experiments.
__label__noRel	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	There may be salutary effects of incretin-based treatments on the diabetic kidney,
__label__Attack	This contrasts with the renal effects of SGLT2 inhibitors, which can be explained concisely.	but the system is complex and not amenable to simple explanation or prior prediction.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	The choice of insulin treatment is not influencing BTMs,
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	metformin treatment may decrease BTMs,
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	Fracture risk is increased in individuals with type 2 diabetes (T2D).	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	The choice of insulin treatment is not influencing BTMs,	metformin treatment may decrease BTMs,
__label__noRel	The choice of insulin treatment is not influencing BTMs,	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	The choice of insulin treatment is not influencing BTMs,	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	The choice of insulin treatment is not influencing BTMs,	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	metformin treatment may decrease BTMs,	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	metformin treatment may decrease BTMs,	The choice of insulin treatment is not influencing BTMs,
__label__noRel	metformin treatment may decrease BTMs,	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	metformin treatment may decrease BTMs,	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	metformin treatment may decrease BTMs,	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	metformin treatment may decrease BTMs,	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	metformin treatment may decrease BTMs,	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	metformin treatment may decrease BTMs,	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	metformin treatment may decrease BTMs,
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	improvement of glycaemic control may influence bone resorption activity.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	metformin treatment may decrease BTMs,
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	HbA1c was inversely associated with CTX but not P1NP.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__Support	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	metformin treatment may decrease BTMs,
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	The choice of insulin treatment is not influencing BTMs,
__label__Support	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	metformin treatment may decrease BTMs,
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__Support	Allocation of insulin regimens was not associated with different levels of BTMs.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	metformin treatment may decrease BTMs,
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	Allocation of insulin regimens was not associated with different levels of BTMs.	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Fracture risk is increased in individuals with type 2 diabetes (T2D).
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	The choice of insulin treatment is not influencing BTMs,
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	metformin treatment may decrease BTMs,
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	improvement of glycaemic control may influence bone resorption activity.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	HbA1c was inversely associated with CTX but not P1NP.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Neither metformin nor rosiglitazone plasma concentrations was associated with BTMs.
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Metformin and metformin + rosiglitazone but not rosiglitazone alone were associated with lower bone formation (PINP).
__label__noRel	BTMs increased from baseline to month 12 and remained higher at month 24, with CTX and PINP increasing 28.5% and 23.0% (all: p < 0.001), respectively.	Allocation of insulin regimens was not associated with different levels of BTMs.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Support	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	The effect appeared to be dose-dependent.
__label__noRel	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).	Further research on dose and mode of treatment is mandatory.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	The effect appeared to be dose-dependent.
__label__noRel	The event-free period (EFP), radiologic course of disease, and survival did not improve.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__Support	Subgroup analyses suggested a dose-dependent treatment effect.	The effect appeared to be dose-dependent.
__label__noRel	Subgroup analyses suggested a dose-dependent treatment effect.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Support	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	The effect appeared to be dose-dependent.
__label__noRel	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).	Further research on dose and mode of treatment is mandatory.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Support	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	The effect appeared to be dose-dependent.
__label__noRel	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).	Further research on dose and mode of treatment is mandatory.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	The effect appeared to be dose-dependent.
__label__noRel	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,	Further research on dose and mode of treatment is mandatory.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__Attack	but other cancer-associated factors seemed to contribute to this toxicity.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	The effect appeared to be dose-dependent.
__label__noRel	but other cancer-associated factors seemed to contribute to this toxicity.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	The effect appeared to be dose-dependent.
__label__noRel	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.	Further research on dose and mode of treatment is mandatory.
__label__noRel	The effect appeared to be dose-dependent.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	The effect appeared to be dose-dependent.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	The effect appeared to be dose-dependent.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	The effect appeared to be dose-dependent.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	The effect appeared to be dose-dependent.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	The effect appeared to be dose-dependent.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	The effect appeared to be dose-dependent.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Attack	The effect appeared to be dose-dependent.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	The effect appeared to be dose-dependent.	Further research on dose and mode of treatment is mandatory.
__label__noRel	Further research on dose and mode of treatment is mandatory.	In the pamidronate group, the occurrence of hypercalcemia, severe bone pain, and symptomatic impending fractures decreased by 65%, 30%, and 50%, respectively; event-rates of systemic treatment and radiotherapy decreased by 35% (P < or = .02).
__label__noRel	Further research on dose and mode of treatment is mandatory.	The event-free period (EFP), radiologic course of disease, and survival did not improve.
__label__noRel	Further research on dose and mode of treatment is mandatory.	Subgroup analyses suggested a dose-dependent treatment effect.
__label__noRel	Further research on dose and mode of treatment is mandatory.	Compared with their controls, in pamidronate HD/LD patients, events occurred 60% to 90% less frequently (P < or = .03) and the EFP was prolonged (P = .002).
__label__noRel	Further research on dose and mode of treatment is mandatory.	In pamidronate LD patients, event-rates decreased by 15% to 45% (P < or = .04).
__label__noRel	Further research on dose and mode of treatment is mandatory.	Gastrointestinal toxicity of pamidronate caused a 23% drop-out rate,
__label__noRel	Further research on dose and mode of treatment is mandatory.	but other cancer-associated factors seemed to contribute to this toxicity.
__label__Attack	Further research on dose and mode of treatment is mandatory.	Pamidronate treatment of breast cancer patients efficaciously reduced skeletal morbidity.
__label__noRel	Further research on dose and mode of treatment is mandatory.	The effect appeared to be dose-dependent.
__label__noRel	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,
__label__noRel	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.
__label__Support	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.
__label__noRel	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.
__label__noRel	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.
__label__Attack	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.
__label__noRel	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.
__label__Attack	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,
__label__noRel	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.
__label__noRel	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.	At 3 months, women treated with 160 mg/d reported less severe side effects (P < .0005), better physical functioning (FLS, P < .0005), less psychologic distress (MHI, P = .008), and an improvement in overall quality of life (FLIC, P = .003) from the time of study entry as compared with those treated with 1,600 mg/d.
__label__noRel	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.	Patients who received the 800-mg/d dose fell between the low- and high-dose arms in reported intensity of drug side effects,
__label__noRel	Unless additional follow-up data demonstrate a survival advantage at higher doses, the 160-mg/d dose is optimal, achieving maximal treatment effect with the fewest side effects and better quality of life.	but responded similarly to those in the 160-mg/d group in terms of physical functioning, psychologic distress, and overall quality of life.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Pulse rate was significantly reduced with timolol, but not with latanoprost.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__Support	Fewer subjective side effects occurred in latanoprost-treated eyes.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Fewer subjective side effects occurred in latanoprost-treated eyes.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__Support	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Pulse rate was significantly reduced with timolol, but not with latanoprost.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Slightly more conjunctival hyperemia appeared in latanoprost-treated compared with timolol-treated eyes.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Fewer subjective side effects occurred in latanoprost-treated eyes.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	no significant difference between treatment groups occurred visual acuity, slit-lamp examination, blood pressure, and laboratory values.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Latanoprost has the potential for becoming a new first-line treatment for glaucoma.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Intraocular pressure (IOP) was significantly (P<0.001) reduced and maintained by both medications without evidence of a long-term drift over 6 months.
__label__noRel	Both eyes of a patient with a characteristic, concentric iris heterochromia (darker centrally) at baseline showed a definite, photographically documented increase in pigmentation during latanoprost treatment, making the irides uniformly darker.	Comparing 6-month with baseline diurnal IOP values, the IOP reduction (mean +/- standard deviation) achieved with latanoprost (-6.7 +/- 3.4 mmHg) was significantly (P<0.001) greater than that produced with timolol (4.9 +/- 2.9 mmHg).
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	although the difference was not statistically significant (P = 0.12).
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__noRel	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__noRel	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	although the difference was not statistically significant (P = 0.12).
__label__noRel	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__noRel	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__Support	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__Support	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	although the difference was not statistically significant (P = 0.12).
__label__noRel	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__noRel	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__noRel	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__noRel	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__noRel	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	although the difference was not statistically significant (P = 0.12).
__label__noRel	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__noRel	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__Support	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	although the difference was not statistically significant (P = 0.12).	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__noRel	although the difference was not statistically significant (P = 0.12).	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	although the difference was not statistically significant (P = 0.12).	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__Attack	although the difference was not statistically significant (P = 0.12).	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	although the difference was not statistically significant (P = 0.12).	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__noRel	although the difference was not statistically significant (P = 0.12).	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__noRel	although the difference was not statistically significant (P = 0.12).	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	although the difference was not statistically significant (P = 0.12).	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__noRel	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__noRel	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	although the difference was not statistically significant (P = 0.12).
__label__noRel	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__Support	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__noRel	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__noRel	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	although the difference was not statistically significant (P = 0.12).
__label__noRel	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__Support	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	although the difference was not statistically significant (P = 0.12).
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__noRel	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.	The number of patients who benefit from treatment is, however, still rather limited.
__label__noRel	The number of patients who benefit from treatment is, however, still rather limited.	The extent to which chemotherapy may relieve tumour-related symptoms, improve quality of life and prolong survival in patients with gastric cancer is not known in spite of the extensive use of this treatment modality.
__label__noRel	The number of patients who benefit from treatment is, however, still rather limited.	More patients in the chemotherapy group (45%, 14/31) had an improved or prolonged high quality of life for a minimum period of 4 months compared to those in the best supportive care group (20%, 6/30, P < 0.05).
__label__noRel	The number of patients who benefit from treatment is, however, still rather limited.	A similar difference was seen in the treating physician's evaluation of whether the patient was subjectively improved or continued to do well for at least 4 months (17/31, 55% versus 6/30, 20%, P < 0.01).
__label__noRel	The number of patients who benefit from treatment is, however, still rather limited.	Overall survival was longer in the chemotherapy group (median 8 vs. 5 months)
__label__noRel	The number of patients who benefit from treatment is, however, still rather limited.	although the difference was not statistically significant (P = 0.12).
__label__noRel	The number of patients who benefit from treatment is, however, still rather limited.	After corrections for imbalances in pretreatment characteristics, chemotherapy treatment was, however, associated with a survival benefit (P = 0.003).
__label__noRel	The number of patients who benefit from treatment is, however, still rather limited.	Also, the quality-adjusted survival time and time to disease progression were longer for patients randomized to chemotherapy (median 5 vs. 2 months, P = 0.03).
__label__Attack	The number of patients who benefit from treatment is, however, still rather limited.	The results show that chemotherapy can add to both quantity and quality of life in advanced gastric cancer.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	There were no significant adverse effects associated with r-HuEPO.
__label__Support	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__Support	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__Attack	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	There were no significant adverse effects associated with r-HuEPO.
__label__Support	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__Support	There were no significant adverse effects associated with r-HuEPO.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	There were no significant adverse effects associated with r-HuEPO.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	The mean hematocrit increased by 6.0 percentage points in the r-HuEPO group versus 1.3 in the placebo group.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	A decrease in transfusion requirement did not reach significance over all 3 months, but there was a significant reduction in the percentage of patients transfused in the second and third months (27% r-HuEPO vs. 56% placebo) and a trend toward reduction in the mean total number of units transfused (1.20 units r-HuEPO vs. 2.02 units placebo), suggesting a lag of 1 month before r-HuEPO can affect the transfusion requirement.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	Pretreatment serum erythropoietin levels were lower in responders than in nonresponders (73.5 IU/L and 86.3 IU/L means, respectively).
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	However, the magnitude of this difference was not helpful in defining which patients were likely to respond.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	There was a significant improvement in overall quality of life between the two treatment arms in favor of the r-HuEPO-treated group.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	There were no significant adverse effects associated with r-HuEPO.
__label__noRel	After 1 month of r-HuEPO, there is also a reduction in transfusion requirement.	r-HuEPO is safe and can cause a significant improvement in the hematocrit and quality of life of anemic cancer patients receiving myelosuppressive, cisplatin-based chemotherapy.
__label__noRel	The Pain Education Program proved to be feasible:	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	The Pain Education Program proved to be feasible:	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	The Pain Education Program proved to be feasible:	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__noRel	The Pain Education Program proved to be feasible:	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__Support	The Pain Education Program proved to be feasible:	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__Support	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	The Pain Education Program proved to be feasible:
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	The Pain Education Program proved to be feasible:
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__Support	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	The Pain Education Program proved to be feasible:
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__Attack	However, pain relief was mainly found in the intervention group patients without district nursing.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	However, pain relief was mainly found in the intervention group patients without district nursing.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	The Pain Education Program proved to be feasible:
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__Support	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.	The use of the Pain Education Program by nurses should be seriously considered on oncology units.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	The Pain Education Program proved to be feasible:
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	75.0% of the patients had read the entire pain brochure, 55.7% had listened to the audio cassette, and 85.6% of pain scores were completed in the pain diary.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	Results showed a significant increase in pain knowledge in patients who received the Pain Education Program and a significant decrease in pain intensity.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	However, pain relief was mainly found in the intervention group patients without district nursing.
__label__noRel	The use of the Pain Education Program by nurses should be seriously considered on oncology units.	It can be concluded that the tailored Pain Education Program is effective for cancer patients in chronic pain.
__label__noRel	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__Support	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__noRel	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__Attack	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__noRel	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__noRel	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__Support	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__noRel	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__Support	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	'Casodex' 150 mg is less effective than castration in patients with M1 disease.	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__noRel	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__Support	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	At a median follow-up period of approximately 100 weeks for both studies, 'Casodex' 150 mg was found to be less effective than castration in patients with metastatic disease (M1) at entry (hazard ratio of 1.30 for time to death) with a difference in median survival of 6 weeks.
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	In symptomatic M1 patients, 'Casodex' was associated with a statistically significant improvement in subjective response (70%) compared with castration (58%).
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	Analysis of a validated quality-of-life questionnaire proved an advantage for 'Casodex' in sexual interest and physical capacity.
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	'Casodex' had a substantially lower incidence of hot flushes compared to castration (6-13% compared with 39-44%) and the most commonly reported adverse events were those expected for a potent antiandrogen.
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	in patients with M0 disease at entry, the data are still immature with only 13% of M0 patients having died.
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	An initial analysis of this immature data has suggested that the results in these patients may be different to those obtained in patients with M1 disease.
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	'Casodex' 150 mg is less effective than castration in patients with M1 disease.
__label__noRel	Thus 'Casodex' 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable.	'Casodex' has shown a benefit in terms of quality of life and subjective response when compared to castration and has an acceptable tolerability profile.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	Group differences were smaller within the psychosocial domain,
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	although trends were seen in favour of the chemotherapy group.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	No significant differences were seen in favour of the supportive care group,
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	except for hair loss.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	No treatment-related deaths occurred.
__label__Support	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	Group differences were smaller within the psychosocial domain,	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	Group differences were smaller within the psychosocial domain,	although trends were seen in favour of the chemotherapy group.
__label__noRel	Group differences were smaller within the psychosocial domain,	No significant differences were seen in favour of the supportive care group,
__label__noRel	Group differences were smaller within the psychosocial domain,	except for hair loss.
__label__noRel	Group differences were smaller within the psychosocial domain,	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	Group differences were smaller within the psychosocial domain,	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	Group differences were smaller within the psychosocial domain,	No treatment-related deaths occurred.
__label__noRel	Group differences were smaller within the psychosocial domain,	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	although trends were seen in favour of the chemotherapy group.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__Attack	although trends were seen in favour of the chemotherapy group.	Group differences were smaller within the psychosocial domain,
__label__noRel	although trends were seen in favour of the chemotherapy group.	No significant differences were seen in favour of the supportive care group,
__label__noRel	although trends were seen in favour of the chemotherapy group.	except for hair loss.
__label__noRel	although trends were seen in favour of the chemotherapy group.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	although trends were seen in favour of the chemotherapy group.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	although trends were seen in favour of the chemotherapy group.	No treatment-related deaths occurred.
__label__noRel	although trends were seen in favour of the chemotherapy group.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Group differences were smaller within the psychosocial domain,
__label__noRel	No significant differences were seen in favour of the supportive care group,	although trends were seen in favour of the chemotherapy group.
__label__noRel	No significant differences were seen in favour of the supportive care group,	except for hair loss.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	No significant differences were seen in favour of the supportive care group,	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	No significant differences were seen in favour of the supportive care group,	No treatment-related deaths occurred.
__label__noRel	No significant differences were seen in favour of the supportive care group,	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	except for hair loss.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	except for hair loss.	Group differences were smaller within the psychosocial domain,
__label__noRel	except for hair loss.	although trends were seen in favour of the chemotherapy group.
__label__Attack	except for hair loss.	No significant differences were seen in favour of the supportive care group,
__label__noRel	except for hair loss.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	except for hair loss.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	except for hair loss.	No treatment-related deaths occurred.
__label__noRel	except for hair loss.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	Group differences were smaller within the psychosocial domain,
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	although trends were seen in favour of the chemotherapy group.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	No significant differences were seen in favour of the supportive care group,
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	except for hair loss.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	No treatment-related deaths occurred.
__label__Support	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	Group differences were smaller within the psychosocial domain,
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	although trends were seen in favour of the chemotherapy group.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	No significant differences were seen in favour of the supportive care group,
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	except for hair loss.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	No treatment-related deaths occurred.
__label__Support	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	No treatment-related deaths occurred.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	No treatment-related deaths occurred.	Group differences were smaller within the psychosocial domain,
__label__noRel	No treatment-related deaths occurred.	although trends were seen in favour of the chemotherapy group.
__label__noRel	No treatment-related deaths occurred.	No significant differences were seen in favour of the supportive care group,
__label__noRel	No treatment-related deaths occurred.	except for hair loss.
__label__noRel	No treatment-related deaths occurred.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	No treatment-related deaths occurred.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	No treatment-related deaths occurred.	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Patients in the chemotherapy group reported better overall physical functioning and symptom control compared with the supportive care group.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Group differences were smaller within the psychosocial domain,
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	although trends were seen in favour of the chemotherapy group.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	No significant differences were seen in favour of the supportive care group,
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	except for hair loss.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Median survival times were 29 weeks in the chemotherapy group versus 11 weeks in the supportive care group, and 1-year survival rates were 28% versus 8%.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	Quality of life and survival outcomes were similar in the randomised and non-randomised patients receiving chemotherapy.
__label__noRel	In conclusion, treatment with carboplatin and etoposide can improve both the quality of life and the survival of patients with advanced NSCLC.	No treatment-related deaths occurred.
